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ABSTRACT - ENGLISH 
 
Resource Utilization in Dementia - a Question of Collaboration 
 
This doctoral thesis investigates one disease management program in dementia located 
in Kalmar, Sweden with regard to the resource utilization. Dementia is a devastating 
disease which mainly affects the elderly. As the disease progresses the need for support 
increases. Dementia is one of the most costly diseases in our society. Although our 
understanding of dementia has advanced we have yet to discover a cure for the disease. 
Nevertheless with our current knowledge we can accomplish a great deal. The 
challenge is to incorporate this knowledge in order to provide high quality care for the 
patients and the caregivers without creating an economic burden for the society. It is 
therefore of interest to evaluate this dementia management program which supports the 
patient and caregiver from diagnosis to death.  
 
In Study I, the dementia management program in Kalmar was assessed. The program 
defined most of the expected new patients per year. And it was introduced within the 
existing budget, after reallocation of resources 
 
In Study II, examined costs of dementia diagnose assessment. Further was the true cost 
per diagnosed patient. Identified for primary care and specialist level. The study found 
that the cost of diagnosing dementia is small compared to the total budget required to 
care for persons with dementia, estimated to be approximately 1% of the total yearly 
cost of dementia in Sweden.  
 
In Study III, the use of selective psychotropic drugs in the elderly in Kalmar was 
compared with Swedish national data. The study found that after the introduction of the 
dementia management program, the use of dementia drugs increased, and the use of 
neuroleptics decreased. Furthermore the use of sedatives and drugs with anticholinergic 
effects was lower in Kalmar as compared to the whole of Sweden. 
 
In Study IV, examined resource utilization in dementia management in the Kalmar 
municipality. The Älvsjö municipality and the whole of Sweden were used for 
comparisons. The results suggest that the cost of dementia care in the Kalmar 
municipality did not increase due to implementation of the dementia program. 
Furtherer suggest the cost for dementia to be from neutrally to lower for the 
municipality of Kalmar compare to the municipality’s in all of Sweden. 
 
The results from this investigation of the dementia management program in Kalmar, 
suggest that most of the new cases of dementia were diagnosed, treated and followed 
up. The cost of the program fell within the existing budget and no extra funding was 
required.  
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ABSTRAKT - SVENSKA 
 
Resursutnyttjande/fördelning vid demenssjukdomar - en fråga om 
samarbete 
 
Denna doktorsavhandling undersöker demensprogrammet i Kalmar län, och studerar 
resursutnyttjandet för demenssjukdomar inom Kalmar kommun. Dess primära fokus 
ligger på primärvården som i samarbete med specialister och Kalmar kommunen är 
gemensamt ansvariga för demensprogrammet. Programmets målsättning är att vara till 
gagn för patienterna och de anhörigas behov, från början till slutet av sjukdomen. 
 
Demenssjukdomar är förödande tillstånd som främst drabbar äldre. I takt med 
sjukdomens progress ökar behovet av stödjande resurser. Idag är demenssjukdomar 
några av de mest kostsamma sjukdomarna för samhället. I och med ett ökat antal äldre i 
befolkningen, som i de flesta länder i världen, beräknas kostnaderna fortsätta stiga. 
Merparten av kostnaderna för demenssjukdomar härrör sig från de senare stadierna av 
sjukdomarna, där det främst faller inom kommunernas ansvarsområde. Utredning och 
insatta behandlingar faller oftast inom landstingets ansvar. 
 
Kunskapen om demenssjukdomar har ökat genom åren. Under de senaste 20 åren har 
det gjorts banbrytande framsteg, men fortfarande finns ingen bot för någon av de olika 
demenssjukdomarna. Tack vare den omfattande kunskap vi har idag från molekylnivå 
till omvårdnad, finns mycket att göra för patienter med demenssjukdomar och deras 
anhöriga. Frågan är hur man skall omsätta denna kunskap till praktik. Hur vi skall 
organisera, samarbeta och styra vården för att stödja patienter och vårdgivare 
professionellt. Detta skall även ske med värdighet och inom ekonomiskt acceptabla 
ramar för samhället. Därför är det av vikt att studera vårdprogram för 
demenssjukdomar såsom det i Kalmar som följer patienten från diagnos till döden.  
 
I studie I, analyseras demensprogrammet i Kalmar. Resultatet visar att 
demensprogrammet fann de flesta av de förväntade nya patienterna per år. Dessutom 
introducerades vårdprogrammet inom den befintliga budgeten. Detta gjordes tack vare 
en omfördelning av de befintliga resurserna utan att annan vård ansågs bli lidande.  
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I studie II, undersöks kostnaden för att ställa en demensdiagnos, både inom primär- och 
specialistvården i Kalmar. Den verkliga kostnaden per diagnostiserad patient 
beräknades. Dessutom att kostnaden för demensutredning till diagnos enligt denna 
modell utgör en procent av den totala årskostnaden för demenssjukdomar i Sverige.  
 
I studie III, studeras användningen av utvalda psykofarmaka hos äldre i Kalmar jämfört 
med hela Sverige. Efter införandet av demensprogrammet, ökade som förväntat 
användningen av demensläkemedel, medan användningen av neuroleptika minskade. 
Samtidigt var användningen av lugnande medel och läkemedel med antikolinerg 
aktivitet lägre i Kalmar än jämfört med genomsnittet i Sverige. 
 
I studie IV, analyseras den kommunala kostnaden för demenssjukdomar inom Kalmar 
kommun. Som jämförelse användes Älvsjö stadsdelsnämn och kommunala kostnader 
från hela Sverige. Studien visar att kostnaden för demenssjukdomar i Kalmar kommun 
inte har ökat på grund av demensprogrammet. Analysen tyder på en kostnadsneutral 
eller en lägre kostnad för demenssjukdomar i Kalmar kommun jämfört med 
medelkommunen i Sverige. 
 
Sammanfattningsvis visar resultaten i denna avhandling att ett demensprogram så som 
man har utformat det i Kalmar, tyder på att de flesta nya fall av demenssjukdomar som 
diagnostiseras, behandlas och följs upp.  Kostnaderna för en demensdiagnos enligt 
modellen är rimliga. Läkemedelshanteringen för utvalda psykofarmaka är bättre för 
äldre jämfört med genomsnittet i Sverige. Kostnaden för kommunen har inte ökat, 
resultaten tyder på en lägre kostnad för demenssjukdomar i Kalmar kommun jämfört 
med Sverige. Kostnaden för programmet genomförs inom den befintliga budgeten utan 
extra tillskott av resurser, detta har genomförts genom en omfördelning och 
effektivisering av de befintliga resurserna. 
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1 PROLOG 
Ten years ago I tought to identify Swedish examples of programs that provided quality 
dementia care. From previous experience I knew that programs designated as “centers of 
excellence” would be a good place to start. Three program, representing three different 
geographical areas in Sweden appeared to exhibit dementia programs that were on the forefront 
of dementia care, Kalix and Piteå in the north and Kalmar in the south. Dementia care in Kalix 
and Kalmar was managed mainly on the primarycare level, while in contrast, dementia care in 
Piteå was managed primarily in the geriatric center at the local hospital. At that time, dementia 
management programs in primary care were coming into focus, which is why I examined Kalix 
and Kalmar more in depth. These two communities addressed dementia management in 
primary care settings by assessing cognitive performance and integrating cognitive deficits into 
diagnostic and treatment evaluations. Subsequently they reported similar outcomes, as 
qualitative comments about the program, including:  
 
 “Fewer patients showed behavioural problems related to dementia”  
 “The use of neuroleptics and sedatives in the elderly was reduced“   
 ” The need for supporting resources, particularly nursing home beds in the 
municipality, was reduced”   
 “The need for acute intervention due to dementia was reduced”  
 
These personal testimonials inspired me to further explore dementia management 
programming, particularly in Kalmar. They were the incentive behind this thesis. 
 
As a symbol for this thesis I have chosen Queen Margaret´s seal from the Kalmar union 
document from 1397. This coat of arms has several meanings for me. First, it represents a 
period of 126 years of peace and collaboration in the Nordic region. Secondly, the three crowns 
in Queen Margaret’s coat of arms, could symbolize the three collaborating organizations in this 
thesis; primary care, the municipalities and specialist care all for the best to the patients with 
dementia and their caregivers. Finally this Nordic union was formalized in Kalmar, where most 
of the material from the thesis has its origin. Also, the illustration of “two upper crowns” could 
represent the dementias, as well as the organizational structure, including: care, governmental 
regulations, and economical base. The lower crown represents the contents of the dementia 
program in Kalmar. 
 
Figure 1. Coat of arms from Queen Magrethe’s seal (1353-1412). The three crowns represent the three 
countries of the Kalmar Union, Denmark, Norway and Sweden (Henrik Klackenberg heraldry of Sweden 
and the artist Vladimir A Sagerlund, the National Archives and the regional state archives of Sweden 
(Riksarkivet)). 
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2 INTRODUCTION  
 
2.1 DEMENTIA 
 
2.1.1 Dementia in general  
Kung Fu Tse is quoted as saying,“Learning without thinking is useless, thinking 
without learning is dangerous” (500 B.C, China), which illustrates the historical 
importance of memory and cognitive functions. It also points to the devastating 
situation that can occur when a person loses cognitive functions. Memory has been a 
challenge to understand. The philosopher Paul Ricœur (1913-2005) “The memory 
may be changing and insidious like a dream, but it is also our most important tool in 
contact with that which no longer exists. ” How to manage dementia has been studied 
to a lesser extent, perhaps partly owing to the lesser importance of studying a strata in 
society whose numbers were relatively small then. Or perhaps people with brain 
diseases were kept hidden within the family. This has changed in the last hundred 
years, as research has brought more knowledge about aging and disease, while the 
elderly population was much increased and a more accepting attitude toward the 
elderly came to be seen in society. The World Health Organisation has classified 
dementia as a major worldwide health challenge [1]. 
Dementia is widespread in modern society. from the prevalence of dementia 
worldwide in 2009 was estimated to be 34.4 million [2]. Anticipated incidence in 
2040 is expected to increase to over 80 million [3]. There were approximately 
150,000 individuals in Sweden in 2008 [4, 5]. This figure is expected to increase to 
250,000 (+67%) individuals by 2050 [6] (Figure 2). As a result, the management of 
the disease is being given high priority by the authorities and politicians in Sweden. 
In 1997 dementia illnesses received priority degree 1B (=illness with reduction of the 
autonomy) [7], which is second only to acute myocardial infarction. The Medical 
Products Agency-Sweden (MPA-S) in 2002 recommended choline esterase inhibitors 
(AChEI) in treatment for mild to moderate Alzheimer disease (AD) [6]. Then the 
Swedish Council on Technology Assessment in Health Care (SBU) made their own 
recommendations for diagnosing and treating AD [8]; and recently the Swedish 
National Board of Health and Welfare (SOS) expressed support for such 
recommendations (SOS) [9]. These were in line with international recommendations 
from USA [10] and UK [11, 12]. 
Of the dementias, AD with or without vascular pathology accounts for 60-75% 
followed by pure vascular dementia, dementia with Lewy bodies and frontotemporal 
lobe dementia. 
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Figure 2. The estimated increase in individuals with dementia in Sweden up to 
2050[13] (printed by permission from the Swedish National Board of Health and 
Wellfare.2010).  
 
The prevalence of dementia is 1% at 60 years of age and doubles every 5 years from 
the age 60 to reach a prevalence of 30-35% at the age of 85. Accordingly, the 
incidence of dementia in Sweden is approximately 25,000 per year [14].  
 
A progressive disease, AD starts insidiously and progressions slowly (Figure 3). It is 
characterized by a wide range of symptoms both within the cognitive domain and the 
domain of everyday function, i.e. the activities of daily living (ADL). Behavioral 
disturbances and psychological symptoms in dementia (BPSD) [15] are important 
symptoms of the disease. 
 
During the disease course cognition declines along with  ADLs [18]. Simultaneously, 
the patients may develop affective symptoms, for example, depression, which can 
precede the cognitive symptoms by years. With increasing severity, BPSD may 
develop, e.g. psychotic symptoms and aggressive behavior. Such behavior is regarded 
as a main factor behind placement in a nursing home [19] and thus a cost driving 
factor. Most of the BPSD symptoms disappear in the final stages of the disease [20]. 
Moreover, new guidelines on BPSD have been drawn up by SBU and MPA-S, which 
emphasise investigation of the underlying causes of the symptoms and caution 
regarding pharmacological interventions [8, 21]. 
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Figure 3. The cognitive decline in Alzheimer’s disease in relation to duration and 
symptoms, nursing home placement and death [16, 17]. 
 
2.1.2 The diagnosis of dementia 
 
A clinical diagnosis of dementia may be offered in the early part of the illness and 
further established many years before death [22, 23]. Diagnostic comparisons are best 
made on the basis of a comprehensive geriatric assessment [9]. 
 
The International Classification of Diseases, 10
th
 revision (ICD-10) [24] and the 
Diagnostic and Statistical manual of Mental Disorders – 4th Edition (DSM IV) have 
established diagnostic criteria for dementia [10]. However, the National Institute of 
Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) [25], was presented 
approximately 25 years ago and is still the golden standard in research on 
Alzheimer’s disease and other dementias.  
 
Dubois and co-workers have challenged these criteria during the last few years [26], 
based on new findings in magnetic resonance imaging (MRI) [8], molecular 
neuroimaging with single positron emission tomography (SPECT), positron emission 
tomography (PET), and cerebral fuel markers such as phospolised β amyloid and Tau 
proteins CSF [27, 28]. 
 
A comprehensive geriatric assessment typically includes medical and social history; 
physical examination; assessment of everyday functioning, such as activities of daily 
level (ADL) and instrumental activities of daily living; laboratory tests; both blood 
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and  CSF, electrocardiography (ECG), electroencephalography (EEG) and and 
imaging study (CT scan, MRI, SPECT or PET); as well as cognitive testing. The SOS 
recommends the Mini Mental State Examination (MMSE) [29] and the Clock Test 
[9]. More extensive neuropsychologic assessments of cognitive function, especially 
memory and attention, lend support to the diagnosis. Whether the assessment leads to 
the correct diagnosis or not is always a matter of debate, especially if it is done at the 
primary care level and not by a specialist [30]. Proper training is essential to increase 
the diagnostic accuracy [31]. It is argued that the definitive diagnosis can only be 
confirmed with certainty by examining the brain at post mortem [22, 23]. However, in 
clinical cross-sectional studies, the diagnosis is always made at least months and 
often years before death. During the interval between diagnosis and autopsy new 
pathological changes occur in the brain. 
 
In the recent launch of the new national dementia guidelines for Sweden, the SOS  
recommends two different levels of dementia investigation [9], namely: a preliminary 
assessment by the primary care physician and a more comprehensive assessment at 
the specialist level. The latter is particularly advised in complicated cases, for 
example that involve younger patients [9].  
 
2.1.3 Psycho-social intervention programs 
 
Presently there is extensive research into use of psycho-social intervention for 
persons with dementia [8]. However individual care remains the keystone in dementia 
treatment [9, 32]. Creating a social inventory can be an important tool to establish a 
knowledge base to guide future interventions. Various psycho-social interventions 
may be used at different stages of the disease (Figure 4) [33-35].  
 
Early on, disease education and psychosocial interventions [36] are important for the 
patient and caregiver in order for them to cope with the physical, emotional and 
practical challenges of the disease. Memory training such as crossword puzzles, 
Sudoku and memory cards can also be of value and should be provided in order to 
train basic cognitive functions. Day care, with a mix of indoor and outdoor activities, 
should also be provided in order to maintain as normal a life as possible [37]. More 
research is required regarding psych-social intervention programs for younger 
patients who are still working in spite of a dementia diagnosis.  
 
In the moderate phase of the disease coping strategies must be supported in order to 
keep up with the daily activities. Validation techniques and memory supporting 
strategies, as well as music and other sensory stimulation could be beneficial.  
Physical activity on both an individual level and in groups is also important, e.g. daily 
outdoor walks. 
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During the severe stage of the disease sensory stimulation techniques such as tactile 
stimulation could improve contact between the caregiver and the patient and at the 
same time have a calming effect on the patient. Activities that strengthen the patients’ 
and caregivers’ self confidence are also important[33-35]. 
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Figure 4. Further exploration of the figure 3 by Jost and Grossberg. In the mild stage 
investment in diagnosis, treatment and education to adaptation to the new situation, 
therefore labeling as acute in this sense. As the disease progress is also the needs of 
support, contributes to the increasing of costs. If treatment such as pharmacological 
and psycho-social intervention can move the illness curve to the left follows usually 
the cost curve along [76]. 
 
2.1.4 Pharmacological treatment in dementia 
 
Pharmacologic treatment has an important role in treating symptoms in AD and 
helping to maintain cognitive ability, and therefore, has provided optimism regarding 
what possibilities exist of treating the disease, and thus bring new hope for this 
devastating condition. Pharmacological treatment should be part of the foundation for 
the care of dementia patients.  
 
Acetycholinesterase inhibitors (AChEI), such as tacrine, donepezile, rivastigmine and 
galantamine, act by inhibiting the enzyme acetylcholinesterase that breaks down the 
acetylcholine in the brain. In several studies these drugs have shown positive effects 
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on cognitive symptoms, global impression and ADL in mild to moderate AD, and in 
some studies even on BPSD symptoms [10, 19, 38-40]; as well as in severe AD [41].  
 
The latest drug in the armamentarium is the non-competitive NMDA-receptor 
antagonist memantine, which has shown effects on symptoms occurring in moderate 
and severe AD [42]. New and promising disease-modulating drugs are currently 
under investigation [43]. 
 
Most health economy analyses regarding pharmacological treatment of dementia have 
suggested a cost-neutral [44] or even a cost-saving effect [45]. However, other authors 
remain skeptical about the health economic benefits of AChEI [46]. Nevertheless, there 
are now recommendations from the SBU, [8] and in 2010 from SOS [9], suggesting a 
more active approach towards treatment with AChIE and memantine. A more active 
approach with early diagnosis of AD and thus earlier treatment initiation may raise 
expectations of postponing nursing home placement [47] and hopefully inprove  quality 
of life for patients and caregivers. However, the treatment should be monitored and 
evaluated, and more research is needed.  
 
2.1.5 The use of drugs in elderly 
 
Internationally and in Sweden heavy drug use by elderly has been an important 
discussion topic [48-55]. Drug related problems in elderly are common, not to 
mention drug-disease interactions [56, 57]. Risk of side effects such as falls [58, 59] 
is of concern. Further the elderly are vulnerable to adverse drug reactions due to age 
related physiological changes, including reduced metabolic and renal clearance 
resulting in increased drug levels, as well as increased sensitivity to drugs due to 
pharmacodynamic changes in many organs. Adverse drug reactions have been shown 
to cause a significant part of acute hospital admissions of elderly [60]. In Sweden, 9% 
of the population is aged 75 years and older [61], accounting for 38% of the total 
amount of drugs in Defined Daily Dosages (DDD) [62, 63]. This is equivalent to one 
quarter of the total cost of drugs for Swedish society. Elderly in Swedish nursing 
homes today receive on average ten or more different drugs daily [64, 65], creating 
the likelihood of increased risk of drug-drug interactions and other drug related 
problems [66]. Several studies suggest that patients with dementia receive more 
psychotropic drugs compared with the elderly in general [67]. At the same time, the 
number of patients with dementia is increasing [14]. There is also a consensus that 
elderly  patients who are already suffering from cognitive disturbances due to 
dementia, are more vulnerable to anticholinergic effects in medication [10, 64, 65, 68-
73]. The increase of intensity and variability of symptoms associated with dementia 
progression is connected to an increased use of drugs with psychotropic action [74]. 
This is problematic, as the elderly are especially vulnerable to the side effects of 
drugs [75]. These drugs include dementia drugs (AChEI and memantine), 
neuroleptics, sedatives, antidepressants and selected anticholinergic drugs (Table 1). 
Antidepressants and dementia agents are considered to have primarily positive 
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cognitive effects, whereas sedatives and neuroleptics may have detrimental influence 
on cognition. For example, agents with anticholinergic activity may precipitate 
delirium in the elderly. Taken together, this knowledge of drugs in elderly may be a 
platform for the implementation of new programs designed to target special 
populations, such as patients at risk of dementia.  
 
ATC-code  Class  Agent  
G04BD  Urinary antispasmodics  emeprone  
oxybutynine  
tolerodine 
N05AA  Antipsychotics, low potency   chlorpromazine  
N05AC02  Antipsychotics, low potency  thioridazine  
N05AC03  Antipsychotics, intermediate 
potency   
melperone  
N05BB01   Anxiolytics,   hydroxyzine  
N06AA   Antidepressants, non-selective  
 
imipramine 
chlomipramine 
crimipramine 
lofepramine 
amitriptyline 
nortriptyline  
protriptyline  
maprotiline 
 
Table 1. Agents with significant anticholinergic activity, frequently used by older 
people in Swede. 
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2.1.6 Disease-management programs in 
dementia care 
 
Disease-Management Program, or specifically Dementia Care Networks, contents of 
broad-ranging aspects of the disease addressing, cost, the multi-modal range of 
resources, and so on (Figure 4). The latter, Multi modal treatment (MT), incorporates 
diagnostics, patient and caregiver education, drug monitoring and other functions. 
There is no cure for AD or some of the other dementia diseases. In addition there is 
also debate on the effects of symptomatic treatment in AD. Of course there is an 
ongoing search for what is the cause of dementia symptoms, and secondly to set early 
diagnoses in order to treat the symptoms early, educate both the patient and the 
caregiver. But finally make it possible for the patient to set up final decision for their 
life’s when they still have the cognitive possibility’s to decisions by self in a dignified 
way. 
 
Studies on the use of MT in dementia care have focused primarily on outcome, e.g. of 
caregiver interventions, of length of time an individual is able to remain in the 
community and not in the nursing home. Several groups have reported quality of 
treatment improvement by caregiver education [77-83] (Table 2). However, many of 
these publications use a broader definition of a disease managing program. Further, 
emphasize the need for collaboration between the different organizations, among 
stakeholders from healthcare, municipality, and private organizations, who are 
together needed to improve the quality of life for the patient and his/her caregiver [9, 
77, 84]. In addition, studies point to the importance of competence, both clinically 
and managerially, or as leaders; as well as professional education of those responsible 
for managing these [85]. Some recent publications emphasize the role of the case 
manager in the geriatric sector [86, 87]. In addition, the influence of caregiver burden 
has been investigated and this demonstrated that the effect was sustained for at least 6 
to 12 months, especially if the intervention was initiated early in the disease [36]. A 
database on dementia programs has been set up in the United Kingdom [88]. Among 
its resources is an education program, as well as a computer-assistive decision-
support system for general practitioners, which aims to improve early diagnosis and 
build concordance with guidelines [89]. Findings are mixed in regards to effects on 
improving caregiver stress and depression [90].  
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Author Year N Population Method 
Effect 
variable Program Time Effect  and main conclusion 
Andre´n, Elmstål 
 
2008 
 
308 
 
Demented  (MMSE 
average 19  
CTR 
 
Time to NH 
 
Psychosocial 
education to 
caregivers 
5 years 
 
Prolonged time to NHP in the intervention 
group 
Brodaty et. al. 
 
1989 
 
96 
 
AD and no AD, mild 
and moderate  
RCT 
 
General health 
of careers. Time 
to NH 
Caregiver education 
vs. memory retraining 
vs. controllers  
1 year 
 
Caregiver education, reduces psychological 
morbidity and longer in home living vs. 
memory retraining       
 
 
1991 
   
LTF 
 
Time to NH and 
costs  
3 years 
 
Caregiver program still superior fewer deaths 
in the training group. Lowes cost in the 
dementia careers program. 
 1993   LTF 
Survival and 
time to NH  
5 years 
 
Caregiver training early in the disease, better 
outcome and later NH placement. 
 
1997 
   
LTF 
 
Survival and 
time to NH  
8 year 
 
Caregiver training early in the disease,  pat 
lives longer  and later NH placement 
Burns et. al. 
 
2003 
 
167 
 
Caregiver of 
demented 
 
RCT 
 
QOL 
 
Caregiver stress-
coping education. 
2 year 
 
Primary intervention with stress coping 
reduces caregiver stress. 
Callahan et. al. 
 
 
 
2006 
 
 
 
153 
 
 
 
Dementia patients 
(MMMSE average 
18 (+5.8) 
RCT 
 NPI  
I year care and 
management study in 
primary care. With a 
interdisciplinary team 
 
18 months 
 
 
Intervention patients more received AChEI and 
antidepressant drugs. Fewer incidences with 
BPSD. Caregivers lower distress, depression 
and patients has lower BPSD score, no 
difference in NHP. 
Chiverton, Cane  
 
1989 
 
40 
 
Spouses to patients 
with AD 
 
CTR 
 
Coping skills 
 
Caregiver education 
 
4 week 
 
No difference in coping ability. Caregiver 
more competent in facing the disease 
progression and knowledge in the intervention 
group. 
Drummond, 
Mohide et.al. 
1991 
 
60 
 
Spouses caring for 
elderly at home 
RCT 
 
Caregiver QOL 
/QUALY 
Caregiver support 
programme 
6 months 
 
No difference in QOL. Cost per QALY 
Can$20,000 favorable the intervention group 
Eloniemi-Sulkava 
et. al. 
2001 
 
100 
 
Demented in need for 
support (MMSE 14,4 
and 15,3) 
RCT 
 
Time to NH 
 
Nurse case 
management 
supporting program 
2 year 
 
NH-placement was less in the intervention 
group in the beginning but similar in the end of 
the trial. 
Fisher, Lieberman 
 
1999 
 
164 
 
Demented resided in 
a home setting at 
baseline 
LTF 
 
Time to NH 
 
No 
 
2 year 
 
High family emotional express etc predicted 
NHP. 
Gaugler et. al. 
 
2003 
 
3944 
 
Demented resided in 
a home setting at 
baseline 
LTF 
 
Time to NH 
 
No 
 
3 year 
 Burden and self related health predicted NHP. 
Gaugler et. al. 
2003 
 
400 
 
Demented using day 
care centers 
CTR 
 
Care giving time 
 
Adult day service 
 
3 months 
 
Day care use reduce behavioral problem, care 
giving time and distress. 
Gilley et. al. 
 
2004 
 
410 
 
Patients resided in a 
home setting at 
baseline 
LTF 
 
Time to NH 
 
No 
 
4 year  
 
Cognitive impairment and behavioral 
symptoms predict NHP. 
Graff et.al. 
 
2008 
 
135 
 
Older demented 
 
RCT 
 
Cost 
effectiveness 
 
Occupational therapy 
 
3 months 
 
Intervention cost effective due to lower cost of 
informal care giving 
Herbet et. al. 
 
1993 
 
41 
 
Caregiver of 
demented 
 
RCT 
 
Caregiver 
burden and 
knowledge 
Support programme 
for caregivers 
8 months 
 
No lower distress for caregivers but higher 
knowledge about the disease in the support 
group  
Lawton et. al. 
 
1989 
 
642 
 
AD (MMSE 
13.7,12,7 (range 6-
30)) 
CTR 
 
QOL for 
Caregiver 
burden and 
NHP  
Respite service for 
caregivers 
1 year 
 
Respite care increased not QOL for caregivers, 
but prolong time to NH, and increased QOL 
for careers 
Martikainen et. al.. 
 
2004 
  
AD 
 
Markov 
model 
Cost and 
caregiver QOL 
Cognitive-behavioral 
family intervention 
5 year 
 
Program cost beneficial over ordinal care. 
Caregiver better QOL.  
Melis et .al. 
 
2008 
 
151 
 
Fragile elderly with 
and without 
Dementia 
RCT 
 
Cost 
 
Geriatric intervention 
program 
6 months 
 
Effective program at reasonable cost. 
 
Mittleman et. al. 
 
1993 
1995 
1996 
206 
 
Spouses to patients 
with AD 
RCT 
 
NH placements 
 
Comprehension 
counseling   
Reduced socioeconomic burden, depression in 
careers and 329 days longer to NH in the 
treatment group. 
Mohide et. al. 
 
1990 
 
60 
 
Caregiver of 
moderate to severe 
demented 
RCT 
 
Caregiver 
depression and 
anxiety 
Caregiver education 
and support program 8 months 
No reduction of Depression and anxiety but 
higher QOL, and some longer time to NH. 
Wimo et. al. 
 
1993 
 
55 
 
Demented in day 
care vs. waiting list  
CTR 
 
NH placement 
 
Day care 
 
1 years 
 
Daycare postponed NH-placement. 
 
Wimo et al 
 
1994 
 
55 
 
Demented in day 
care vs. waiting list 
CTR 
 
QOL, costs 
 
Day care 
 
1 year 
 
Lower cost per day for day care patients no 
difference in QOL. 
Wolfs et.al.  
 
2007 
 
230 
 
Patients with psycho 
geriatric problems 
CTR 
 
QOL 
 
Multidisciplinary 
diagnostic facility 
 
6 and 12 
months 
 
QOL improver in intervention group.  
 
 
Table 2. Multi modal treatment programs in dementia some additional cost analysis 
and long term follow [78, 79, 86, 87, 91-113](RCT=Randomize clinical trial, 
CTR=Clinical trial, LTF=Long term follow up, QOL=Quality of life, QUALY= 
Quality adjusted life years and NH=Nursing homes). 
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2.1.7 Health economics and dementia 
 
The already high cost of dementia care is expected to increase dramatically due to a 
rising incidence rate [114], prompting interest by government leaders in identifying 
cost-effective strategies for assessment and treatment. Empirical studies have been 
lacking [8]. In order to study long-term cost-effectiveness of treatments for society, 
economic models are frequently that are based on estimating the costs of the decline 
in cognitive function [76, 115]. Alternatively, other models focus on other variables, 
such as impairment in everyday functioning, typically measured by ADL [116]. A 
study on AD, BPSD and costs found 30% of the costs of AD  is related to managing 
of BPSD [19]. This is noteworthy, as these non-specific symptoms are the main factor 
behind the inability of patients to remain in their homes thus leading to nursing home 
placement [15]. In addition, studies that analyzed relative costs associated with 
selected types of dementia, including vascular dementia and Lewy-body dementia, 
suggest greater costs when compared with pure AD [117, 118].  
 
When evaluating health economic studies it has been important to consider whether 
both care of the patients and education of caregivers are taken into account. Both 
positive and cost-neutral studies are presented (Table 2) [119]. Most of this cost 
analyses is performed in models due to methodological issues to not catch the long 
term effects, has been debated [120], and double-blind randomized trials are 
recommended. Studies have reported 80-85% of the economic burden for dementia 
care in the Swedish health care system are shouldered by municipalities; and making 
this a concern for all [13, 14]. Moreover, suggests caregiver education and dementia 
day care centers can provide economical benefit and perhaps prolong the length of 
time leading to nursing home placement (Table 2) [36, 121]. Furthermore, suggest the 
SOS in the National dementia guidelines, multi modal economical consequences for 
the county council and municipalities respectively, both in context of short and long 
term effects. [32]. 
 
Quality of life (QOL) for patients and caregivers has been difficult to investigate. 
Jönsson and associates suggested (2006) that the patients are rather stable in the 
perception of QOL during the progression of the illness. In contrast to the proxy-
reported utilities where  the patients QOL similar in the milder phase but lower than 
the patients in the more severe stages of the illness [122]. There is a general high 
consensus related to the effects with caregiver education and support, in order to 
enhance the QOL of the caregiver. But more research related to the QOL in patients 
related to treatment seems to be needed [123]. 
 
2.1.8 Impact on society 
 
The incidence of dementia disorders, and the increasing severity of this chronic disease 
over time, will together create even greater burden on patients, caregivers and 
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society[124].  The total cost worldwide is estimated to156.2 billion USD, 119 billion € 
[125]. In UK dementia costs over 1% of the total gross domestic product, and stands as 
one of the most costly diseases [126]. In line with this, the total cost of dementia care in 
Sweden was estimated to be 5 billions € in 2005, with 85% of the cost being borne by 
the local municipalities. The incidence of dementia disorders is expected to rise to 
250,000 by 2050 and costs will increase accordingly [14].  
 
The need for support for the patient and his/her caregiver will increase following the 
loss of the patient’s abilities [124]. Many caregivers are dissatisfied with the support 
from professionals and society while they concern themselves with day-to-day 
management [2, 127]. The optimal organization response to the need for care and 
support services is a “chain” of professionals (Figure 6) having a variety of different 
skills [128]. In the early stages of the disease, the identification of cognitive decline, 
loss of attention and sensitivity to stress are often the symptoms that set the 
diagnostic process in motion [129]. The first line in the diagnostic process is usually 
the primary care unit or a municipal administration alternative a social worker, social 
or a welfare officer. Once the diagnosis has been established, it is important to offer 
support and education for the patient and his/her caregiver to cope with the new 
situation this presents. This might be done either within the primary care setting or at 
the specialist level. As functional loss progresses caregivers may become 
overwhelmed by the burden to care for the patient. At such a time added support from 
the municipality should be made available to compensate. Costs consequently 
increase as the more severe stages of the illness emerge (Figure 4) [130]. Some 
examples of these types of support are help from municipalities staff in the patient’s 
own home, day care centres, temporary stays in a nursing home, and permanent 
residence in a nursing home. Several different professionals are simultaneously 
involved in the care of dementia patients, ranging from specialists to GPs to various 
types of nursing professionals and skilled workers, physiotherapists, occupational 
therapists, social workers, social welfare officers, municipal coordinators, municipal 
officers, municipal administrators, etc. This implies that several different and parallel 
organizations hold responsibilities, which require communication and close 
collaboration in order to obtain a satisfactory outcome during the illness progress 
[131]. Moreover, regional and country differences in organization and culture, 
influences how economical investigations are to be undertaken. Subsequently, when 
data is collected it is difficult to analyze and report generalized results from health 
economical analyses from country to country [132].  
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2.2 FUNDING, ORGANIZATION, GOVERNMENTAL REGULATIONS, 
STRUCTURE OF CARE 
 
2.2.1 Funding, organization and regulations 
 
Funding will usually follow parallel the organization like paralellell pipes (Figure 5). 
Decentralized organization and management models follow a Nordic tradition and 
corresponds to this pattern of funding [133]. The needs of the patient and his/her 
caregiver should guide the work and planning of the organization [7]. Over the course 
of disease management the management responsibility may shift among various 
stakeholders. Funding has to be obtained and should benefit the patient through until 
the final stages of the disease. Provision is made for this by “Hälso och 
sjukvårdlagen,” a county council and municipal organization role. Further regulation 
of municipality social and welfare activities embody the social services law, known 
as, “Socialtjänstlagen,” as well as “Lagen om Stöd och Service till vissa 
funktionshindrade” that benefits individuals with disabilities, patients younger than 
65 years.  
 
One can argue pro and con for a decentralized organization and for general laws and 
regulations regulate and guide disease management programs. The positive with local 
budget could be the commitment to the own sphere of activities and two have control 
of resurses and costs. But it also has a conflict to have an overall outlook of long term 
investments and general needs for the patients and the community [133]. 
Governmental regulations and the service organization guidelines may sometimes 
conflict (rising e.g. in ethical conflict, such as determining the balance of the medical 
needs versus the autonomy of the patient). Day-to-day management of such conflicts 
is necessary. However, a further intent with the laws and regulations is to bridge the 
general needs between different stakeholders and minimize local variations. Swedish 
social law and welfare has launched new recommendations stipulating that persons 
with dementia shall be taken care of from early recognition and diagnosis onto the 
final stages of the disease. Further, it is mandated that a local organization should be 
set up in order to harmonize the process, though the effectiveness of these is unknown 
[9]. 
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The Community
The County Councils
Hospital
primary care
etc.
The Municipality
Elderly care  including nursing 
homes , day care centers and
social services
Patients with dementia and 
caregivers
 
Figure 5: Organization and funding are like “pipes” with no formal interaction 
despite the changing needs of the patient.  
 
2.2.2 “Chain of care” 
 
Logistics can be described as the management of the flow of goods, services, 
information and other recourses including people. The term comes from the military 
history, and is associated with optimizing support for soldiers [134]. A focus on 
optimizing service delivery has been to minimize costs by improving logistic flow of 
items, goods or services from A to B to C etc. In the health care sector a term 
denoting this is medical logistic management. The complexity of the health care with 
the variety of independent factors, is a challenge to analyse and organize [135].  
 
In this study the Disease-Management Program is offered as one step to further 
implement a “logistic health chain,” especially with regard to chronic diseases, such 
as dementia. One must contend with numbers of different professionals and 
organizations that become involved during the course of disease (Figure 6). Creating 
demands that range across a number of domains, and which call for a variety of 
different provider types must operate within a chain of care incorporating a multi-
functional network [84]. Additionally, there is the problem of untimely, or late, 
observation suggesting that indeed a problem is present. Olofsdottir and associates 
suggested (2001) that the patient who has received a dementia diagnosis had visited 
primary care at least 5 times the previous year [129, 136]. 
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Primary care or/and
Specialist
Municipality
Home support, Day care shelter and 
Nursing homes 
Follow up  
Identify the 
problem
Diagnose 
process
Treatment 
and 
education
Adaption 
and  
support
Further 
support
and caring
Terminal 
care
”Wissel blower”
•Self or/and caregiver
•Primary care (GP, Community Nurse, etc)
•Municipality (social worker, etc.)
Others
 
Figure 6. The dementia process presented in a logistic perspective “chain of kneads 
and care”. From identify the problem, symptoms and to be noticed/visible as a 
patients. To the final stages of totally dependency and high level of caring, associated 
with high costs.  
 
2.2.3 Disease-management program 
 
Disease-management programs are often described in the literature as "a system of 
coordinated health care interventions and communications for populations with 
conditions in which patient self-care efforts are significant. [137-139]”  
Disease-management programs are usually planned using both cost and service 
quality components, mandated to reduce costs and improve quality of life (QOL) 
(Figure 8). This is achieved by preventing or minimizing the effects of various 
conditions through integrative care and assessment [140]. These have evolved from 
managed care and typically concern chronic diseases and conditions, ombining the 
evidence-based quality care with costs. Typical disease-management programs have 
been set up to manage chronic diseases, such as cardiac and pulmonary diseases, 
hypertension, obesity, diabetes mellitus, asthma, cancer and depression[138]. 
Disease-management programs have come about often with the support of caring 
organizations associated with specific diseases. Often research has provided 
important information that led to one or another group starting such as program. 
Investigation of the quality of these programs must rely on local cooperation, though 
disease-management programs can be regional, national, or even international. All 
have unique political and social interests with may influence the aim to examine 
quality. Learning from organization development and the management of change in 
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organization, one should not be surprised if there is resistance to developing a 
disease-management programs. Resistance may be observed, for example, when 
physicians and others health care personal are forced to participate in a program, or 
when the program restricts the choices decisions about care [140]. 
 
Disease-management programs incorporate monitoring and evaluation functions. The 
their goal is not necessarily to cure but to improve quality of life for the patients, and 
caregivers without increasing costs (Figure 7). A similar concept in dementia- and 
stroke-care is the term “health services delivery networks” [84, 90, 141]. 
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Figure 7. Modelling the theoretical effect of disease-management programs; for the 
same investment recourse utilization and higher service grade and a flexibility of 
reducing costs without decrease the initial service grade (modification from figure by 
Folland et al [140] ) . 
 
2.2.4 Operations Management and Lean 
Production 
 
The organization in pipes (Figure 6) where is not always followed the patient flow. 
To overcome this can an operation management (OM) system been set, in order to set 
up the chain of care in the logistic framework. Thus is the program strengthen [140]. 
The positive with this framework is too justified sometimes locally unpopular 
decisions who increases the costs in one organization but lower the costs in another. 
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Further is framework of OM a guaranty to the political and higher organizations 
levels to ensure the quality and equality overall treatment. The logistic care chain and 
the management program can be followed, majored and evaluated. 
 
In order to improve the production cold the concept of Lean Production be of interest. 
The concept was first introduced in the automobile manufacturing industry during the 
1980´s, mainly at Toyota. It embodies a general customer focus and aims to achieve 
regular improvement in production. Recently Lean Production was introduced in the 
health sector in a process framework. Lean Production suggests to consists of five 
central elements or statements. First, the organization can always be better with 
involvement from the co-workers. Secondly, to eliminate all unnecessary actions, this 
improves work flow, and enables standardization. Third, establish general and 
attainable goals. Fourth, perform regular measurements and give feedback. Finally, 
implement regular improvements in the process [142]. Overall, Lean Production can 
provide a platform collaboration and communication, and help to form a higher-
quality productive process. 
 
2.2.5 Dementia care organization in Sweden 
 
The care of persons with dementia in Sweden is shared between the  county councils 
the municipality’s (Figure 5).  
 
2.2.5.1 County council 
 
2.2.5.1.1 “Memory clinic” 
 
Memory clinics provide specialist care in dementia assessment and care planning, and 
are mainly located in hospitals. With respect to managing dementia assessment and 
care, specialists were originally primarily geriatricians, though gero-psychiatrists and 
neurologists have performed much of these services as well. Patients are referred out 
of primary care practice to these specialists, though referral may occur directly to the 
specialist while bypassing primary care[9]. In addition, day assistants in the dementia 
diagnostic process are may include neuropsychologists, who perform tests of various 
cognitive domains, and physiotherapists who observe the ADL.  
 
2.2.5.1.2 Primary care 
 
The Primary Care Units (PCU) are multidisciplinary organizations that include 
physicians and are typically organized by catchment area, serving a pool of 
subscribers or members. Such PCUs serve healthcare needs from “cradle to grave.”. 
Additionally, PCUs act as “gatekeepers” coordinating access to other components of 
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the health care system [140], e.g. directing patients to the appropriate and most cost 
effective treatment.  
 
Barriers to optimal performance of these units have been identified, including: lack of 
support, time and financial constraints, stigma, diagnostic challenges, and disclosing 
the diagnose [143]. Patients may visit the PCU frequently before the diagnosis of 
dementia is made [144]. Thus, PCUs have a unique opportunity to identify dementia 
early in its course.  
 
Diagnosing dementia accurately is also an issue.  Some studies have suggested that 
the rates of accurate diagnoses may improve with education, and even be an 
instrument helping to detect new cases [145, 146], others suggests mixed results with 
training [147]. Thus in the recommendation from the SOS suggests the primary care 
be responsible in the basic level of the dementia investigation [32]. 
 
2.2.5.1.3 Emergency- and further -department   
 
Patients who are cognitively impaired may present in any number of ways in the 
hospital, e.g.in the emergency department (ED). Nevertheless, these patients are 
frequent visitors to primary care units [8, 144, 148, 149]. Furthermore, in the period 
before turning up at the ED, elderly patients have lost most of their social contacts 
resulting in isolation [150, 151]. A study on elderly patients undergoing the transition 
from homecare to nursing home care report corresponding increase in visits to the 
ED, mostly due to falls, fever, cardiovascular diseases, gastrointestinal problems and 
cognitive impairment [152]. Such cognitively impaired patients also present to 
medicine, orthopedic, psychiatric service though more studying of this issue is 
necessary. Thus is a further factor complicating the rehabilitating process for example 
after a hip fracture has been a debate of a longer rehabititation period [153-155]. 
 
2.2.5.2 Support care governed by Municipality  
 
Most municipalities are more directly involved in managing dementia care, which 
should be understood to provide a mixture of care and support to patient and 
caregiver. Home care, for example, is supported by the municipality. In addition, 
municipalities may support sheltered-day-care services, both to provide relief to the 
caregivers and to provide daily activity to the patient. Under some conditions, nursing 
home placement, whether for temporary or permanent lengths, may be supported by 
the municipalities. In the more severe stage is often placement to nursing home 
necessary temporarily or permanently. 
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2.2.5.2.1 Day care center 
 
New dementia guidelines in Sweden strongly recommend day care centers. These 
sites may be helpful in providing services, including memory training and 
rehabilitation, which may also provide respite for caregivers [9].  
 
2.2.5.2.2 Home service support 
 
In order that cognitively impaired remain home as long as possible home service 
support should be utilized. A project has been described in which special dementia 
team were developed to provide home support to patient and caregivers [131]. The 
efficacy of such programs need to be further evaluated..    
 
2.2.5.2.3 Technical devices and support 
 
In recent years technical devises have been increasingly used within the domain of 
dementia care, including special clocks, mobile telephones, GPS-devices that assist 
with supervision, as well as sophisticated robots that may have roles in certain 
activities within their repertoire. More research will be needed to see the pros and 
cons of their use. Further also the legal aspects e. g. the autonomy of the patient has to 
be addressed.  
 
2.2.5.2.4 Nursing home 
 
Having the prospect of an advancing course of dementia patients and their families 
are likely to face a decision to move to a nursing home. This kind of support is the 
most costly form of care in the dementia chain [14]. On other hand support in the own 
living at home might be more costly. Nursing home support can provide care for full 
24-hour days. Municipalities invest also in temporary nursing homes. This inpatient 
type of could be a temporary support for tree times as many patients.  
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2.3  THE SETTING AND DEMENTIA MANAGEMENT PROGRAM IN 
KALMAR 
 
Kalmar, Sweden, has approximately 60,000 inhabitants and age distribution similar to 
Sweden as a whole. A dementia-management program (DMP) was established that 
involved the primary care system, specialists, and the social welfare officer (SWO), the 
latter which represented Kalmar municipality [75]. Implementation began in 1998 at 
the point of the primary care system.  Earlier the task of  diagnosing dementia was 
handled by the geriatrician. The municipality had a caring organisation according to 
normal setting in Sweden.  
 
The preliminary reason for implicate the program was to change focus from the 
historically “ad hoc” to a “costumer need” solution within the primary care. Studies had 
demonstrated that patients not yet having been diagnosed but who nevertheless 
demonstrated cognitive impairment  were frequent visitors to primary care and needed 
to be identified early [129, 144]. An operations manager was appointed to focus on 
dementia care programming and was mandated to set up a multi-disciplinary dementia 
team.  
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caregivers
DN 
GP
GP
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Figure 8. The Dementia team in Kalmar works cross functionally in-between and over 
the organizations and economical boundaries. The primary care and specialists is in 
the main domain of the county council. Where’s the municipality acts separately. 
 
When these began data was not easily available, for instance the number of patients 
visiting the primary care system was not known. Moreover, guidelines for the process 
of clinical evaluation of patients with neurocognitive impairment were absent. Nor 
were there guidelines for managing patients with dementia within the organisation. 
Lines of authority were not described, and there was a lack of accountability over how 
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services were being monitored and resources being allocated. The organisation was 
vertically-organized (parallel organizational bodies with no organized collaboration in-
between). There were no formal mechanisms for collaboration between geriatric 
specialists and the municipality that would help to make more efficient the support of 
patients and caregivers.  
 
The operation manager orginized a team and identified a singel nurse from each PCU 
who was appointed Dementia Nurse (DN) to collaborate with a dedicated SWO from 
the municipal organisation (Figure 8). The team was supposed to work cross  
functionally (woark over the formal organization) and collaborate horizontal (in stead 
of vertical) between the different organisation for the benefit for the patients and 
caregivers. 
 
Initially, an inventory of the patients with a dementia diagnosis was made and 538 
patients were identified as having either an established or a possible diagnosis of 
dementia. The calculated prevalence of individuals with dementia is in an area of 
60,000 inhabitants is over 900 patients within Kalmar municipality. Education 
programming was started in the primary care organisation and included the GP, 
municipal nurses, assistant nurses and the home care and nursing home staff. 
Educational programs were extended to political and administrative officers, both 
within the county council and the municipality, in order to gain system-wide support.  
 
The main components of the DMP were early identification, diagnosis, treatment and 
follow up. In order to minimize the number of individuals involved in the patient 
management process. The process of assessment began with all new cases were 
referred directly to the DN, obtaining a health history from the patient and caregiver, 
enabling the GP assigns and “established diagnosis” of dementia based on ICD-10. 
Standard operating procedures (SOP) were established that incorporated a basic 
diagnostic battery, including medical and social history, physical examination, 
laboratory tests, ECG and CT scan (Table 3).  
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Basic assessment  Supplementary assessment as required  
 Patient  and relatives informed that 
assessment has been initiated  
 Medical history  
 Life and social history  
 S-TSH  
 Electrolyte status incl. calcium  
 Blood status  
 Blood glucose  
 P-Homocysteine  
 MMSE  
 Clock test  
 Orthostatic blood pressure series  
 Medical examination incl. neurological 
status 
 Drug monitoring vs. indications and 
potential risks  
 ECG  
 CT scan of brain  
 Guardianship certification  
 Driving license assessment  
 Possession of firearms  
 Care planning  
 Patient and relatives informed of the 
results of the assessment  
 Cholesterol  
 Liver status  
 Liquor analysis   
 EEG  
 Neuropsychological testing  
 AMPS  
 Driving license test  
 
 
Table 3. The Standard Operating Procedure (SOP) in establishing dementia diagnose 
in primary care setting[156]. 
 
The DMP aimed to standardize diagnostic procedures, including:  comprehensive 
reviews of drug and medical history, cognitive performance screening , using the Mini-
mental Status Examination (MMSE) and the Clock Test, physiotherapy and 
occupational therapy assessment, as well as assessment by a psychologist if needed. 
 
The SWO is introduced early during the assessment process to assist in planning and to 
offer support. Younger patients (below 65 years) and other cases considered more 
complex were to be referred to the specialist for further evaluation and diagnosis 
(Figure 9). The diagnosed patients were offered medical treatments and psycho-social 
intervention.  
 
A mechanism was created so that the team could regularly monitor patient progress. 
The team focused on continued improvement of the monitoring mechanism  (Figure 6). 
As in Lean Production [142], all co-workers were involved in this process. A schema of 
functional flow of actions was developed. Feedback sessions were incorporated with 
the regular program monitoring results. In order to a attainable goal. It is notable that 
the dementia management programs today suitable in the context of the newly 
presented Swedish dementia guidelines [32]. 
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Patient
Caregiver
GP
Community nurse
Etc.
Specialist
Dementia nurse
Psychologist
Dementia diagnosisPending/MCINo dementia diagnosis
General practitioner
Dementia nurse
Follow up
 
 
Figure 9.  Flow of patients in the Kalmar dementia investigation programme, part of 
the response of the county council, but also is usually the SWO involved in the process 
early even without that it is necessary with support from the municipality. But it is of 
help in linking to the future needs of support. 
 
A role of the DN is to guide the patient and his/her caregiver through the health care 
system, to inform about them about different aspects of the disease and to support the 
families in the day-to-day care. In addition, the DN is responsible for setting up 
educational programs for caregivers and for patients in the early stages of dementia. 
The education is usually performed in groups divided in two parts. The first part has 
three sections (I, II, III): I, dementia diseases, what happens in the brain pathology and 
epidemiology. II, what help is available from the municipality? III, coping strategies for 
daily life and best practice of treatment and the care about the persons needs. The 
caregiver may request further education and meetings which the municipality then 
provides. 
 
Once diagnoses are established, treatment is started, and is continued through the 
“follow-up phase.” The DN becomes responsible to set up and manage regular 
appointments, most of which are attended by the DN. However, at least once a year the 
patient is seen by the GP. Moreover the DN is also responsible for managing 
appointments concerning other co-morbid medical conditions [157] . However, the 
responsibility of medical care shifts over to the municipality if and when the patient 
becomes a regular nursing home resident.    
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3 HYPOTHESES AND AIMS 
 
3.1 FOLLOWING HYPOTHESES HAVE BEEN IDENTIFIED FOR THIS 
PROJECT 
 
 The dementia management program is reliable to define most of the new 
patients per year. (Paper I) 
 What is the (mean) cost of a complete assessment for dementia at the level of 
(specialist or PCU), and how does this compare with the total cost of dementia 
assessment, treatment, and care during the full course of disease? (Paper II) 
 The dementia management program has additional influence on prescription 
patterns in the elderly population, to a more proper use of psychotropic, 
including sedatives, dementia drugs and drugs with anticholinergic properties. 
(Paper III) 
 Implementation of dementia management programs does not increase cost 
burden of managing dementia for the municipality. (Paper IV) 
 The dementia management program is at least cost neutral when applied in 
both county council and municipality. (Paper I, III and IV) 
 
3.2 AIM OF THIS THESIS 
 
The aim of this thesis is to identify and describe the dementia management program, 
and to evaluate it with respect to health economic costs and benefits.  In doing so this 
thesis will advance understanding about some aspects of the relationship between 
stakeholders, as for example, cost-sharing between county councils and 
municipalities. Such evaluation requires a deeper understanding of the Kalmar DMP 
organization structure and process that influence the full scope of activities associated 
with its responsibilities in dementia care and overall disease management. Further, 
this thesis aims to develope understanding of how to promote optimal care and 
treatment of dementia patients both from the clinical and economical perspective. In 
order to investigate these aims the following questions were defined:  
 Can the program identify the number of new patient with dementia per year in 
the area? 
 What is the cost of a dementia diagnose with this program? 
 Has the use of selective psychotropic drugs used by elderly changed after the 
introduction of the dementia program? If so in what direction? 
 What are the costs of dementia for the municipality after the introduction of 
the dementia program? 
 Is it possible to implement the DMP including collaboration between primary 
care, specialist care and the municipality within the existing allocation of 
funding and resources?  
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4 MATERIAL AND METHODS 
 
4.1 MATERIAL AND STUDY POPULATIONS 
 
4.1.1 Study 1 (paper I) 
 
In study 1,  patients from the inventory which were based on data obtained in 1997 
with defined as having either an established or a possible dementia diagnosis (n=538). 
The sample from DN records in Kalmar, including the number of (new or existing 
cases) cases exhibiting possible dementia cases from 1999 to 2005 , (n= 1500). 
Further, all patients with their first registered dementia diagnosis between 1995 and 
2005 in Kalmar County council are entered into the central diagnosis database 
(n=1307), with a dementia diagnose. According to the SOS, the prevalence of 
dementia is defined as the average duration (by years) [158]. Descriptive statistics of 
from the general Swedish population and the local Kalmar populartion was obtained 
from Statistic of Sweden [159].  
 
4.1.2 Study 2 (paper II) 
 
The second study described patients referred for dementia assessment between 
January 2004 and April. Thirty consecutively referred patients undergoing dementia 
assessment beginning in January 2004, along with ten consecutive patients referred 
for specialist assessment of dementia at Kalmar county hospital were analyzed 
(Figure 10).  
I. GP
30 consecutive
patients
5
patients referred to 
specialist
II. Specialist
10 consecutive 
patients
13
dementia 
diagnosis by 
GP
9
dementia 
diagnosis by 
specialist
10
no dementia
2
others
1
no dementia
 
Figure 10. Patient distribution in study 2 (paper II) 
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4.1.3 Study 3 (paper III) 
 
The third study examined elderly patients (75 years and over) who were receiving 
prescribed drugs from Swedish pharmacies during the period from 2000 to 2005. 
These included dementia drugs, neuroleptic, sedative, antidepressant drugs, as well as 
other drugs with significant anticholinergic properties.  
 
4.1.4 Study 4 (paper IV) 
 
The fourth study described a sample of patients who had been diagnosed with 
dementia who were utilizing municipality resources in Kalmar (2002-Q2 2004; 
n=570) and Älvsjö (2003-2005; n=187). 
 
 
4.2 METHODS AND ETHICAL APPROVAL 
 
The project involves both a retrospective and prospective analyses. Specific 
discussion of the methods used will be presented in the separate papers. Later in this 
thesis analyses will be presented. A triangulated model [160-162] is used in order to 
analyze the DMP in Kalmar with a multidimensional perspective. 
 
4.2.1 Study 1 (paper I) 
 
The study was both retrospective and prospective, including several components: 
firstly, a comparison of the demographics of Kalmar compared with Sweden as a 
whole; secondly, analysing the diagnostic investigations of individuals with cognitive 
impairment in Kalmar municipality; thirdly, an analysis of patients’ contacts with the 
PHC. Finally, we analysed all known dementia patients in 2005 in the area. 
Furthermore, we compared the estimated incidence and prevalence figures for 
dementia in the municipality of Kalmar with Sweden as a whole. 
 
4.2.2 Study 2 (paper II) 
 
We carried out a prospective time and resource utilisation study in order to identify 
the total costs associated with the diagnostic process for dementia within the dementia 
program. This was done both at specialist and primary care level.  
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4.2.3 Study 3 (paper III) 
 
The study is a retrospective population based drug utilization analyseis with a 
longitudinal and cross sectional. In order to identify drug consumption in the elderly 
(75 years and elderly [163]), we selected the following types of drugs for further 
investigation: dementia drugs, antidepressants, sedatives, neuroleptics, sedatives and 
drugs with significant anticholinergic properties as they are often used by the elderly 
population and are known to have both positive and negative effects [64, 68, 164], 
especially when used together. To obtain comparable data between Kalmar 
municipality and Sweden as a whole, we analysed the use of drugs sold at Swedish 
pharmacies, expressed as DDDs [63] per 1000 inhabitants and year. This measures 
the quantity of drugs used in this population. The collection of data covers the period 
from the year 2000 to 2005, when the Dementia Program was fully implemented. 
Furthermore, in order to analyse prescription habits (how many were using a specific 
drug in the population), we also performed a cross sectional analysis of the Swedish 
Prescribed Drug Register (SPDR) [165]. We analysed individual-based data from 
individuals aged 75 years and older who were registered in the SPDR during October-
December 2005. Based on, information from the three-month period , including the 
date when the prescription was issued, the amount of drug received, and the 
prescribed dosage, the current drug use on december 31, 2005 could be estimated  
[163, 166].  
 
4.2.4 Study 4 (paper IV) 
 
Study four reports on analysis of direct costs for dementia care, i.e. cost-of-illness 
(COI) on both retrospective and prospective with a municipality economic 
perspective. Direct costs of the county councils, costs of informal care and indirect 
costs due to production losses of patients were not included. The main focus was on 
Kalmar municipality. In order to examine representativeness of the area and potential 
program effects in terms of directs costs we included comparisons as contrasts to 
Kalmar with Älvsjö municipality and Sweden as a whole [14]. Älvsjö was selected 
due to not have a dementia program such as in Kalmar. We used a cost analysis 
model with three basic components: volumes of used resources (including all major 
municipality costs related to the dementia care i.e. help in home, day-care centres and 
nursing homes, both on temporary and permanent basis (A) [14], unit costs for each 
resource (B) and an estimate of the number with dementia that used these resources 
(C): (A*B*C=MC). The source for the quantities of used recourses is the formal 
support decision by the SWO. An increase by 20% for estimated overhead costs was 
included. In addition, we compared these findings with the estimated cost of illness of 
dementia in Sweden [14]. In order to compare socioeconomic status between the 
areas figures about education and income proportions were obtained from Statistic 
Sweden [159] All costs are adjusted to the year of 2002 based on the Consumer price 
index (CPI).  
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4.2.5 Ethical approval 
 
The study was approved by the ethic committees in Linköping, Dnr. 03-494 (paper I-
IV), Karolinska Institutet, Stockholm Dnr 2006/948-31(paper III) and Karolinska 
Institutet Dnr 239/03 (Paper IV). 
4.2.6 Statistical analysis 
 
4.2.6.1 Study 1 and 4 (paper 1 and IV) 
 
The statistical software package SPSS version X and Microsoft Excel were used for 
the statistical analyses. All variables were summarized using standard descriptive 
statistics such as mean, standard deviation, and frequency. Comparisons between 
national and local data (gender, age, diagnoses and frequency of patents with 
dementia and costs) are based upon population data. 
 
4.2.6.2 Study 2 (paper II) 
 
The calculation was done on 30 patients in primary care and 10 patients at the specialist 
level. The true patient cost calculation was based on the average cost of dementia 
investigations for all patients who received a dementia diagnosis including the cost for 
those who did not receive a dementia diagnosis divided by the number of patients 
diagnosed with dementia.  
 
4.2.6.3 Study 3 (paper III) 
 
No analyses of statistical significance were performed, as the data are based on whole 
populations. A logistic regression analysis was used in the cross-sectional part, in order 
to analyze the use of neuroleptics, anxiolytics, sedatives, selective serotonin reuptake 
inhibitors (SSRIs), dementia agents and drugs with anticholinergic properties in Kalmar 
compared to Sweden as a whole. Adjustments were made for age, gender and number 
of drugs. The relationships are expressed as odds ratios (ORs) with 95% confidence 
intervals (CIs). 
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5 MAIN RESULTS, COMMENTS AND RELATED 
CONCLUSIONS 
 
The primary findings from the four papers outlined above are summarized here, while 
the full articles are to be found in the appendices. Note that between the years 2000-
2005, the percentage of the population of Kalmar that is “elderly” (about 17.3% >65) 
is nearly the same as the percentage within the general population of Sweden (17.5% 
in Sweden) as can be seen in Table 4. 
 
 
2000 2001 2002 2003 2004 2005 Mean  
Sweden (SD)  8875038 8888496 8903540 8919814 8937156 8955422 8913244 (±24625)  
≥65 (SD) 1530593 1531564 1534349 1540913 1550821 1559753 1541332 (±8394)  
≥75 (SD) 790748 793730 794668 796602 795908 796799 794743 (±2289)  
≥80 (SD) 453051 465267 472306 478638 483265 486847 473229 (±11877)  
Proportion ≥ 65 17,2% 17,2% 17,2% 17,3% 17,4% 17,4% 17,3% 
Proportion  ≥75 8,9% 8,9% 8,9% 8,9% 8,9% 8,9% 8,9% 
Proportion ≥80  5,1% 5,2% 5,3% 5,4% 5,4% 5,4% 5,3% 
Proportion 
woman  ≥65  58% 58% 57% 57% 57% 57% 57% 
        
Kalmar (SD)  59 308 59 787 60 066 60 415 60 649 60 924 60192 (±593)  
≥ 65 (SD) 10 460 10 509 10 493 10 568 10 591 10 565 10531 (±51)  
≥75  (SD)  5 483 5 498 5 492 5 536 5 521 5 530 5510 (±22)  
≥ 80 (SD)  2 736 2 818 2 861 2 964 3 000 3 016 2899 (±112)  
Proportion ≥ 65  17,6% 17,6% 17,5% 17,5% 17,5% 17,3% 17,3% 
Proportion ≥75  9,2% 9,2% 9,1% 9,2% 9,1% 9,1% 9,1% 
Proportion ≥80  4,6% 4,7% 4,8% 4,9% 4,9% 5,0% 5,0% 
Proportion 
woman ≥65  59% 59% 59% 59% 59% 59% 59% 
 
Table 4. Population and proportionality (in percent) of elderly in Sweden as whole 
and Kalmar municipality. 
 
5.1 PAPER I 
 
5.1.1 Hypothesis 
 
 The dementia management program is reliable to define most of the new 
patients per year. 
 The dementia management program is at least cost neutral when applied in 
both county council and municipality. 
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5.1.2 Setting 
 
The first study was based on yearly reports made by the DN, which were delivered to 
the dementia operational manager. Further, county council records were used to 
determine the situation that existed prior to introduction of the dementia management 
program. Subsequently, epidemiological data obtained on dementia in Sweden and 
Kalmar, was used for comparison.  
 
5.1.3 Results 
 
On average, 214 (range 160–257) patients were evaluated per year of which 127 
individuals (range 113–157) obtained a dementia diagnosis at the primary care level 
(Table 5). Additionally, 22 patients per year were diagnosed at the local geriatric 
clinic. The number of patients registered locally in the PHC by the DN is in line with 
the central registry of diagnoses within the county council (Figure 11), a deference of 
less than 10%. 
  1999 2000 2001 2002 2003 2004 2005 Mean 
Total  
(SD)  
206 160 192 240 257 203 242 
214.3 
(±33,9)  
Proportion women (%) 68 64 63 62 48 61 51 59.6  
Living alone (%) – – 64 51 48 61 51 54.9 
Support from caregiver (%) 39.8 51.3 42.7 34.2 31.9 40.4 33.9 39.2 
Mean age women – – 81 – 80 82 80 80.8 
Mean age men – – 79 – 79 78 77 78.3 
Diagnoses and referrals                 
No dementia (SD)  56 33 32 40 53 49 82 49.3 (±17.2)  
Suspected dementia (SD) 28 14 42 43 59 33 44 37.6 (±14.2)  
Referrals to specialist (SD) 19 26 17 29 31 28 20 24.3 (±5.5)  
Final diagnoses                  
Alzheimer’s disease (SD) 51 44 51 62 66 42 42 51.1 (±9.6)  
Vascular dementia (SD) 29 35 21 45 23 28 22 29.0 (±8.6)  
Frontotemporal 
dementia(SD)  
3 3 5 3 5 1 1 3.0 (±1.6)  
Levy Body dementia (SD) 0 4 2 2 1 1 1 1.6 (±1.3)  
Mixed dementia(SD) 10 9 21 19 33 40 39 24.4 (±13.0)  
Unspecified dementia (SD) 29 18 18 26 17 9 11 18.3 (±7.3)  
Total with a dementia 
diagnosis from PH (SD) 
122 113 118 157 145 121 116 
127.4 
(±16.7)  
 
Table 5. Registration from the PHC (Primary Health care centres) of patient 
referrals for dementia investigation during the introduction of the dementia 
programme in the Primary health care organization in Kalmar community from 1999 
to 2005. 
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Figure 11. Registrations of diagnosed dementia patients from the County council 
(PHC=Primary Health care centre’s, GR=Geriatric clinic, IMED=Internal medicine) 
and reporting from private physician in Kalmar community from 1995 to 2005. 
“Others” includes patients from other departments, such as infectious diseases, 
surgery and private physicians.  
 
Most patients who entered the DMP  began their diagnostic assessment after being 
referred by a physician and were followed by nurses within the primary care 
organisation. The municipality has introduced new patients with less numbers. The 
number of visits to a GP within the primary care organisation remained stable during 
the length of the observation period. The absence of comparative data before 2000 
made an earlier comparison impossible. 
 
5.1.4 Comments 
 
The expected incidence and prevalence of dementia cases in Kalmar are approximately 
153 and a prevalence of 889/949 (2000-2005 respectively). An important element in the 
program is that all patients with cognitive impairment are entered when whenever 
dementia is suspected. Thus, if it is assumed that only new dementia cases are entered 
into the “program,” and that there are no false-positive or false-negative cases the 
detection rate of dementia in PHC was 129/153(84%). That number of patients, 129, 
when added to the patients diagnosed in the specialty clinics, is roughly equal to the 
expected annual incidence during the study years, or 153. Since the number of 
diagnosed patients is similar to the expected incidence, we may assume that the 
program is able to identify a major proportion of new cases. Furthermore, as the 
program continues, the dementia cases that are not diagnosed in one particular year 
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may be identified in subsequent years. Other studies have found that when GPs are 
trained in the diagnosis of dementia, the detection rate is acceptably accurate [136] but 
the distribution of the different types of dementia in Kalmar correlates with earlier 
studies, suggesting acceptable diagnosis [4, 167]. Improvement in diagnosis as a result 
of the dementia program maybe also reflected in corresponding decrease in the 
numbers of  ”unspecified dementia diagnoses”. Finally, the 1997 inventory showed that 
316 patients had a diagnosis of dementia (35%) of estimated prevalence. In 2005, 601 
cases were identified in the inventory, corresponding to 63% of the estimated 
prevalence. 
 
At the time the program was introduced in Kalmar the number of visits to the GPs was 
an unchanged but a decreased in visits to the PHC nurses. No data are available to 
indicate the number of patient visits through the program in Kalmar. The turnover of 
PHC staff in Kalmar has been fairly unchanged during the observation period. No extra 
funding was needed and the number of staff somewhat unchanged.  
 
5.1.5 Conclusions 
 
 The study found that the dementia management program is probably capable of 
identifying the same number of individuals with suspected dementia as are 
expected according to epidemiological estimations of incidence.The dementia 
management program was able to achieve the objective above without requiring 
addition expenditure of money, though requiring reallocation of resources. 
 
5.2 PAPER II  
5.2.1 Hypothesis 
 
 What is the (mean) cost of a complete assessment for dementia at the level of 
(specialist or PCU), and how does this compare with the total cost of dementia 
assessment, treatment, and care during the full course of disease? 
5.2.2 Setting 
 
This study was based on time and resource utilisations analysis of the process 
associated with dementia assessment in both primary care and specialist levels locally 
within Kalmar County.  
5.2.3 Results 
 
Where the dementia management program was utilized at the primary care level, 
dementia assessments took between two weeks and two months to arrive at diagnosis. 
The patients were seen on average three times per year by the GP and four times 
annually by the DN the year before diagnosis. The average length of time used for 
assessment of dementia was 1.45 hours for the GP and 4 hours the DN. The average 
cost for all included patients at GP level was 477 Euro (€) (Table 6). For those who 
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after evaluation received a dementia diagnosis by the GP, the mean cost was 654 €, 
while the corresponding costs for those referred to a specialist for further evaluation 
were 459 €. In addition to the average cost at GP level, the extra cost at specialist level 
was calculated to be 656 €. Thus, the total cost for the final diagnosis at specialist level 
was 1115 €. As some of the evaluated patients were not assigned a diagnosis of 
dementia, the total cost for cases diagnosed with dementia is the same as the cost for all 
dementia investigations divided by the number of definitive diagnoses.   
 
 Dementia 
diagnosis  
Referral to 
Specialist and 
diagnosis  
No Dementia  Others  Total  Mean  
PHC (n)  13  5  10  2  30   
Mean cost  653.9 €  459.1 €  297.6 €  274.2 €    
Total cost  (SD) 8500.7 €  2295.5 €  2976.0 €  548.4 €  14320.6 
€  
477.4 € 
(±275€) 
Total cost no diagnosis 
(SD)  
  2976.0 €  548.4 €  3524.4 €  293.7 €  
(±185€)  
Weight proportion 
diagnosis vs. remittent 
and diagnosed by 
specialist  
0.72  0.28      
Cost per positive 
diagnosis (true cases) 
by GP  
653.9+195.2=
849.1 €  
    849.1  €  
Cost per positive 
diagnosis of those 
referred to a specialist  
 459.1+197.2  
=656.5 €  
    
Specialist (n)   9  1  -  10   
Mean cost (SD)  643.3 € (±206€) 306.3 €  -    
Cost per positive 
diagnosis (true cases) 
by specialist  
 1333.9 €     1333.9 €  
 
Table 6. The cost (€) per positive dementia diagnosis (true cases) in the Primary 
Healthcare Centre (PHC) diagnosed by General Practitioner (GP) and by specialist.  
 
5.2.4 Comments 
 
This study showed empirically what was actually done during the diagnostic process. 
Most of the costs came from the time used by the physicians and the DN but to some 
extent came from different technical diagnostic investigations such as MRI and 
SPECT. The costs at the specialist level were, as expected, higher than in primary care, 
as these cases are more complicated and require further investigation, such as lumbar 
puncture for analyzing biomarkers, such as, tau and beta-amyloid(Aβ). Cost of positive 
cases was higher than for negative cases, consistent with a targeted approach in which 
clinicians halted the process when appropriate.  
 
Since the proportion of (what to what) are similar in Kalmar as in the whole of Sweden, 
extrapolation may be allowed, for example with regard to the number of confirmed 
dementia cases in Kalmar over the total Kalmar population, one could extrapolate the 
expected incidence in Sweden [168], In our study, 2 out of 3 cases  had a confirmed 
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diagnosis while in the Kalmar five-year follow up study [168] about 50 % of patients 
with a suspected dementia had a confirmed diagnosis. Thus, we assume that the 50 % 
figure is more appropriate for the estimated national cost. We have estimated, therefore, 
that since there are about 24,000 new cases of confirmed diagnosis of dementia in 
Sweden annually [14], the number of needed diagnostic procedures (if we assume that 
the need corresponds to incident cases) would be expected to be double, or 
approximately 50,000 individuals to investigates.   
 
Furthermore, if we assume that the proportion of referrals to a specialist is similar in all 
of Sweden as in Kalmar (1/3), our rough estimate would be 15,000 specialist diagnostic 
procedures per year. This is in line with the results from a Swedish study initiated by 
the SOS which showed approximately 13,200 cases [131]. Thus, the estimated yearly 
total cost for dementia diagnoses in Sweden is 13.4 million € (4400 *1334€  + 8800 * 
849 €), which is similar to earlier estimations of 13.6 million € [131]. This is, however, 
a low estimation since the cost for dementia diagnoses in primary care for patients that 
are not referred to a specialist is unknown. Furthermore, if we assume that there is a 
need for approximately 50,000 diagnostic investigations, the costs under optimal 
conditions could be three fold, or in any case comparable to the estimated total societal 
costs of dementia in Sweden calculated at about 4.7-5 billion € [14]. 
 
5.2.5 Conclusions  
 
The cost of the diagnostic procedure if this dementia management model is applied to 
the rest of Sweden is approximately 1 % of the total cost for dementia.  
 
5.3 PAPER III   
 
5.3.1 Hypothesis 
 
 The dementia management program has additional influence on prescription 
patterns in the elderly population, to a more proper use of psychotropic, 
including sedatives, dementia drugs and drugs with anticholinergic properties. 
 
 The dementia management program is at least cost neutral regarding the local 
use of target drugs.  
 
5.3.2 Setting  
 
The paper is based on drug utilization data provided by the Swedish drug delivery 
company (Apoteksbolaget AB), which at the time for this investigation had a monopoly 
on the drug market in Sweden.  
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5.3.3 Results  
 
Results showed that patterns of prescription changed in a manner that appears to be 
associated with the dementia management programs. Examination of drug use, 
expressed as DDD per 1000 inhabitants aged 75 years and older (see the methods), 
showed that prescription patterns of dementia drugs increased more in Kalmar (289%) 
than nationally (142% in Sweden) between year 2000 to 2000. The proportion of 
dementia drugs prescribed by GPs increased from 42% to 86%, during which time the 
dementia management program was being implemented. In 2005 the use of dementia 
drugs in Kalmar was higher than in Sweden as a whole (204 %), probably due to 
patients initiated by the GP. However, during this same time prescription pattern of 
dementia drugs among specialists did not change. Antidepressant drugs on the other 
hand showed consistent prescription patterns in both local primary care program data as 
in the national data. Also both local and national data showed reduction in prescription 
pattern of older antidepressants (-26%), as well as with anticholinergic drugs. However, 
each of these drug types showed increases during the observation period. Selective 
serotonin-reuptake inhibitors (SSRI) showed similar elevation in prescription pattern in 
both local and national data. Prescription pattern of hypnotics was lowered in Kalmar (-
22%), as was the use of benzodiazepines (-15%). Analysis of SPDR data showed 
proportions of users in agreement with the long term follow up analysis 2000 to 2005. 
In addition, neuroleptics, anxiolytics, sedatives and drugs with anticholinergic 
properties were used to a lower extent in Kalmar (Table 7). During the first three years 
after the introduction of the dementia program, we observed a more pronounced 
decrease in use of neuroleptics in Kalmar (local) compared to Sweden (national). In 
Sweden, there was a 13% decrease in use of neuroleptics from 2000 to 2005. However, 
in 2005, the use of neuroleptics by the elderly was 30% lower in Kalmar than in 
Sweden as a whole. 
 
 Kalmar (n=5036)  Sweden total 
(n=732230)  
OR  
(95% CI)  
Neuroleptics (N05A)  148 (2.9%)  33071 (4.5%)  0.71 (0.60-0.84)  
Benzodiazepines (N05B)  384 (7.6%)  68644 (9.4%)  0.90 (0.81-1.01)  
Sleeping agents (N05C)  1032 (20.5%)  167338 (22.9%)  0.95 (0.88-1.02)  
SSRI antidepressants 
(N06AB)  
577 (11.5%)  82957 (11.3%)  1.15 (1.05-1.26)  
Dementia agents (N06D)  271 (5.4%)  20481 (2.8%)  2.14 (1.89-2.43)  
Drugs with anticholinergic 
properties  
 
270 (5.4%)  42007 (5.7%)  1.05 (0.92-1.19)  
 
 
Table 7. Number and proportion of persons (%) using neuroleptics, benzodiazepines, 
sleeping agents, SSRIs, dementia agents and drugs with anticholinergic properties 
among those 75 years and older in Kalmar and Sweden, 2005. The relationship 
between area, Kalmar community vs. Sweden, and usage is expressed as an odds ratio 
(OR) adjusted for differences in age and gender distribution. Data from the SPDR. 
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5.3.4 Comments 
 
The relatively larger increase in prescription patterns of dementia drugs in Kalmar 
compared to the Swedish national figures may be a direct effect of the dementia 
program. However, this corresponds to approximately 40% of treatable patients with 
the indication, suggesting no excessive treatment. Guidelines put forward by SOS 
suggests that all patients with Alzheimer disease AD be offered dementia drug 
treatment [9]. In addition, SSRIs are recommended for depression, a condition 
frequently seen in elderly patients especially in combination with dementia [20]. 
Therefore, the somewhat higher use of SSRIs in Kalmar may be seen as positive, 
although this needs to be further explored. Drugs that may cause side effects in the 
elderly [64] include neuroleptics[68, 169], anxiolytics, sedatives  and drugs with 
anticholinergic properties. In Kalmar, we observed reduced prescription patterns for all 
of these drugs compared to Sweden as a whole. Notably, the rate of decrease of 
neuroleptics was most prominent during the three first year of the dementia program 
and was observed to remain level in the years following.  
 
The cost of dementia drugs in Sweden increased by 32% and the corresponding cost in 
Kalmar by 50%. Despite this the total cost of the targeted drugs, cost in Kalmar was 
unchanged while the cost at the same time increased with 26% in Sweden. In addition 
the dementia program was implemented without any extra resource allocations. Finally, 
it is notable that the cost for dementia drugs accounts for only 1% of the total cost for 
dementia care in Sweden [14].  
 
During the dementia program (2000-2005), 1458 cognitively impaired individuals were 
initially identified in primary care [168]. All of these individuals were evaluated 
regarding their drug use. 
 
5.3.5 Conclusions 
 
 The prescription pattern for investigated drugs among elderly in Kalmar differs 
from Sweden as a whole: 
o Increased use of dementia drugs  
o Lower use of sedatives  
o Lower use of drugs with anti-cholinergic properties 
o Decreased use of neuroleptics in elderly after the introduction of the 
dementia managing program followed by a stabilization at a lower level. 
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5.4 PAPER IV 
 
5.4.1 Hypothesis 
 
 Implementation of dementia management programs does not increase cost 
burden of managing dementia for the municipality. 
 The dementia management program is at least cost neutral when applied in both 
county council and municipality. 
5.4.2 Setting  
 
The paper is based on data provided by the municipalities of Kalmar and Älvsjö, as 
well as epidemiological and cost data from the whole of Sweden. 
 
5.4.3 Results 
 
5.4.3.1 Population 
 
Local data was obtained from Kalmar and Älvsjö, and national data from Sweden. 
Demography is the proportionally in terms of age-groups, Kalmar is similar to Sweden 
as a whole, wheras Älvsjö has a younger population. Further has Älvsjö a larger 
proportion of individuals with higher education, followed by Kalmar, but both have a 
population that is somewhat better educated than in Sweden on average. Regarding 
income: has Älvsjö the highest level of income followed by Sweden and Kalmar. The 
standard number of long term care beds in Kalmar was lower in Kalmar Sweden as a 
whole. 
 
5.4.3.2 Municipal dementia data for Kalmar 
 
During the period January 2002 to June 2004, 576 patients with dementia were 
recorded. Most of these patients had received support in various ways, such as 
occasional hours of help at home, regular home help, day care centre 1-5 days per 
week, temporary or permanent resident in a nursing home. Based on epidemiological 
figures the estimated number of deaths amongst those with dementia was 150/year. 
Thus the records indicate that approximately ten percent of these individuals were 
living at home with home healthcare, care at a day centre or intermittent nursing home 
care at the time of death. Fifty percent died as nursing home residents and 40 % died 
without using any municipal resources.   
 
5.4.3.3 Municipality data for Älvsjö 
 
One hundred and eighty-nine patients with dementia were defined from January 2002 
to December 2005. From the start of the study, the data were rather sparse but as a 
result of the study the authorities became more and more aware of the benefit of 
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reliable data and thus our data also became more and more robust. The estimated 
number of deaths amongst people with dementia in Älvsjö was 50 per year. Thus, at the 
time of death, ten percent where estimated to have home care, day centre care or 
temporary care in a nursing home whilst 59% were estimated to die as permanent 
nursing home residents. Finally, 31% died without using any municipality resources. 
 
5.4.3.4 Cost 
 
Municipal records obtained for the study period showed that the proportion of 
patients with a dementia diagnosis who also utilized resources was 61% (n=576 of 
estimated 949) in Kalmar and 63% (n=187of estimated 298) in Älvsjö (Table 3). 
Assuming that all other demented persons not included in the cost model are not -
users of care, the yearly municipal cost-per-patient (based on the estimated total 
number of persons with dementia) in Kalmar was 14,206 € (in year 2003), which 
compares with 10,610 to 13,184 € in Älvsjö (in years 2003-2005). Using national 
figures for comparison the corresponding cost was 23,600 and 29,871€ in 2000 and 
2005, respectively. However, based on the actual number of persons that are included 
in the cost model, the cost per person with dementia person in Kalmar 2003 was 
26,334 €, 26,025 to 30,464 in Älvsjö and 27,594 and 36,459 in Sweden (Table 8). 
 
 Kalmar   Älvsjö   Älvsjö   Älvsjö   Sweden   Sweden   
Year  2003   2003   2004   2005   2000   2005   
Municipality 
costs (number)  €  %  €  %  €  %  €  %  €*1000  %  €*1000  %  
Elderly care cost €              
Home care  13363238  40  4821846  40  5372023  43  5867157  43  1850070  27  1963714  27  
Day care  879903  3  265777  2  303761  2  294384  2  121490  2  128952  2  
NH and Respite care  19352667  58  6945782  58  6945782  55  7586729  55  4878488  71  5178095  71  
SUM  33595808  100  12033405  100  12621566  100  13748270  100  6850048  100  7270762  100  
Dementia cost €              
Home care  2598858  19  156902  5  157149  5  341563  9  536000  17  860400  20  
Day care centres  490573  3,6  44276  1,4  118555  3  150935  4  39000  1  41900  1  
Respite care  645790  5  111282  4  67320  2  85759  2  943200  30  860900  20  
Permanent NH  9746718  72  2849389  90  3071413  90  3350482  85  1620600  52  2484500  58  
SUM  13481939  100  3161849  100  3414437  100  3928739  100  3138800  100  4247700  100  
Estimated number 
with dementia  949   298   298   298   133000   142200   
Cost per patient vs. 
estimated  14 206 €   10 610 €   11 458 €   13 184 €   23 600 €   29 871 €   
Dementia cost %   40   26   27   29   46   58  
Number of patients 
in the model  415   76   119   127   113750   121105   
Cost per patient in 
the model (SD)  
26 334 €  
(±15 955 €)   
29 040 €  
(±18 845 €)   
26 025 €  
(±18 956 €)   
30 464€  
(±18 585 €)   27 594 €   35 075 €   
 
Table 8. Municipality costs in elderly related to dementia in 2003 in Kalmar, Älvsjö 
and the whole of Sweden. The cost from Kalmar and Älvsjö is derived from the 
municipality records. The elderly and dementia cost from Sweden 2005 and 2000 
(calculated) is from two reports from publication by the National Board Of Health and 
Welfare [14, 170].  
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5.4.4 Comments 
 
The municipalities in Sweden spent 3-4 billion € annually on dementia care during the 
years from 2000-2005 [14]. On the other hand, if the total cost figures (for example in 
Kalmar 13.5 million € in 2003, based on 415 persons) are assumed to represent all costs 
of the total dementia populations in the study areas (in Kalmar 949 persons), it is 
implicitly assumed that those not included (949-415 persons) are non users of care. 
This “hidden” subpopulation in the municipality records may include true non users, 
but also individuals with diagnoses receiving care from the dementia nurse and 
caregiver. Moreover, those not diagnosed with dementia (most of them probably with 
mild dementia) or those incorrectly- classified may utilize some resources, resulting in 
an underestimate of costs. Thus the cost figures per demented individual in Kalmar are 
14,206 € (extrapolated to assumed whole dementia population) to 26,334€ (based on 
known study population) can be regarded as a min-max interval. Compared to the 
corresponding Swedish cost estimate for municipal care (29,871€ – 36,459€) the 
figures indicate, nevertheless, lower costs in Kalmar. This interpretation is supported by 
the lower standardized figure of long term care in Kalmar (53 beds per 1000 65+) as 
opposed to Sweden (71 beds per 1000 65+), since long term care is the major cost 
driver of formal care.  
 
If we assume that the program in Kalmar reduces costs or at least is cost neutral, one 
may regard the program as successful. First, most patients were identified early in the 
disease which facilitated early intervention and supported care planning, caregiver 
support and training, drug review and symptomatic drug treatment. Secondly, the 
dementia nurse becomes a mentor along the whole course of the disease. The support 
the caregiver receives from the dementia nurse in ordinary, daily activities is the most 
valuable contribution. Thirdly, the social welfare officers become involved in the 
patient and caregivers´ situation early in the disease, facilitating support when home 
care or nursing home placement is required. Fourthly, caregivers can better cope with 
their situation when they know that support is available. Finally, if a problem arises the 
program provides easy accessibility, either to the dementia nurse or the physician. All 
of these benefits may positively influence the cost of care, but they also signify an 
improvement in the quality of care as a result of the program. In addition, less use of 
neuroleptics in the elderly and higher use of dementia drugs with a cost consequence 
approach, the program may be regarded as cost effective.  
 
5.4.5 Conclusions 
 
 The dementia management program was not associated with increased the cost 
of dementia for the municipality. Further, the cost of dementia per patient for 
Kalmar municipality suggest to be similar level per patient, but total cost at a 
lower level than the rest of Sweden.  
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6 DISCUSSION 
 
6.1 SUMMARY OF MAIN FINDINGS 
 
 The dementia management program in Kalmar identified and registered the 
expected number of new patients per year (incidence). 
 The dementia management program was implemented without increasing cost 
 Based on the actual cost of diagnosing dementia in the Kalmar and using this 
cost figure to estimate national cost, we project from this data that diagnosing 
dementia is but 1% of the total cost of dementia care in Sweden. 
 The prescription pattern among elderly in Kalmar differs from the rest of 
Sweden: 
o Higher use of dementia drugs 
o Lower use of sedatives 
o Lower use of drugs with anticholinergic properties 
o Decreased use of neuroleptics 
 The cost of dementia for the municipality did not increase during 
implementation of the dementia management program. 
 The cost-of-dementia per patient with dementia for Kalmar municipality was 
lower than national cost-of-dementia in Sweden. 
 
6.2 DISCUSSION OF THE MAIN FINDINGS 
 
The main finding suggests that the dementia program in Kalmar is effective in 
identifying and diagnosing new patients. Patients and caregivers are hereafter followed 
during the course of the disease with collaboration with primary care and the 
municipality. The cost has not increased due to the program despite there being more 
patients with identified needs. Furthermore the findings suggest that the general drug 
treatment to elderly regarding psychotropic drugs is more optimal to the elderly issues 
compared to the whole of Sweden. Moreover, earlier presented findings related to 
elderly visiting emergency department in Kalmar suggest a decrease with 15% visits, 
during the introduction of the dementia program [171]. In view of using a triangulation 
model (se method) [160-162] analyzing these findings all together, it can be argued that 
the dementia management program in Kalmar works as intended. Moreover suggesting 
associated additional effects as long during the introduction of the DMP. Both in drug 
utilization in elderly and a lower frequency of acute incidences in elderly. Thus was this 
possible within available budget recourses, further suggesting to more optimal recourse 
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allocation than the rest of the country. Additional assessments are conducted during the 
period that the patient is being followed, including obtaining information regarding 
caregiver attitudes and needs. The education program was identified as the primary 
positive component by the caregiver (Gustavsson E. personal communication). Similar 
finding were supported from Ontario Dementia Care Networks [172]. Secondly has an 
analyses been performed identifying why some healthcare program (chains of care) 
were successful and others were not [173]. Three major determinants of integrated 
health care development were identified: professional dedication, legitimacy and 
confidence [173]. The Kalmar dementia program was defined in the successfully range. 
 
Koch et. al. defined three main factors that enhance the capability for primary care to 
identify, diagnose, treat and follow up patients with dementia [174], including: First are 
skills together with education, secondly is financially and economical, and final is 
organization and multi disciplinary approach. In scope of this is the Kalmar dementia 
program involved in at least organization and skills. Thus the economical part is 
included not as an incentive, but as suggesting to be better resource utilization. 
 
This study identified in the Kalmar dementia program some significant attributes. 
Collaboration was demonstrated both horizontally and vertically. Callaham et. al. 
suggested that collaburation in a primary care setting has been suggested to be 
benificial improving the qality of care, lowering BPSD withoot incresing neuroleptics 
and sedatives [95]. Collaboration has been described at different levels, such as in the 
local organization, in and between organizations, and between stakeholders. Such 
collaboration can help overcome challenges faced within different organisations, such 
as the county councils and municipalities. Organizations having such programs in place 
remain intact with one budget, maintain local resources and existing framework, and 
thus present no conflict with other agency resources. Such programs benefit from 
having been set up locally and shareholders have been involved in planing and 
development the process promoting factors for success. Finally the program has been 
approved by the different operators in the system, such as local politicians, regional 
stakeholders, etc. [173] and therefore supported by them.  
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6.3 METHODOLOGICAL ISSUES, LIMITATIONS AND 
GENERALIZABILITY 
 
This thesis reports on the evaluation of the Kalmar dementia managment program. A 
major focus in this study was on primary care. Evaluating the full scope of the program 
was problematic due to the disease complexity and the sheer number of professionals 
and organizations involved. We selected a quasi-experimental cost-of-illness method 
and used national figures for comparison. However this method has some limitations. 
We did not compare Kalmar with any other community.  Alhough a direct comparison 
might have been useful, finding another community for exact comparison is 
unreasonable. First, doing so would have outstripped the capacity of this study to 
address ethical and strategic issues regardin how patients with dementia are treated.  
Second, it is nearly impossible not to interfere with ongoing measurement in a 
controlled area without interfering.  
 
A limitation of the studies represented in this thesis is the absence of QOL evaluative 
information from the perspective of patients and caregivers. Also, “indirect costs and 
other additional costs” are not defined and incorporated in the overall study.  
 
Information regarding validation of diagnoses of dementia does not describe what 
effort was made to compare against a “gold standard,”. However, the validation of 
clinical diagnoses was considered outside the scope of this thesis. Neither was there 
investigation of possible impacts on other departments at the hospital beside some 
minor analyses in emergency department. In order to compare the findings we have 
not use a controlled area similar to Kalmar. Instead we used the total of Sweden as 
comparison (Paper 1-IV) and Älvsjö as comparison area in (paper IV).  
 
6.3.1 Population 
 
Distribution of age in the Kalmar sample was not obviously dissimilar from national 
figures in Sweden, and thus, this did not dissuade our using these for comparison in 
papers I, III and IV and paper II in the calculation of the total cost of dementia 
investigations in Sweden as a whole. Some minor differences in gender, income 
distribution and educational levels can almost be ignored in this respect. Furthermore, 
the proportionality in the population suggests generalizability to population’s 
comparisons to the rest of Sweden.  
 
6.3.2 Organization 
 
The analyzed dementia program fulfils most of the criteria to be a disease management 
program. First, there is coordination of the healthcare between different stakeholders. 
Secondly, there is a clear definition and responsibility of who is doing what in this 
collaboration. Thirdly, there is a part (run by the DN) taking care of education and 
support to the patient and caregiver, supporting better self-care efforts. Forth, there is an 
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intention to be as cost neutral as possible, in spite of that no regular total cost evaluation 
where done. Finally the continually caring of patients with dementia might serve as a 
model for a “chain of care”. This concept is suitable in a logistic framework in order to 
the illustrate the need of a cross functional operational management working in a Lean 
Production environmental such as in the dementia management program in Kalmar. 
 
The Kalmar program was chosen for this study because it offered unique advantages, 
such as having local support to build it from the earliest planning stage. Further the 
dementia program in Kalmar is specific for that region. The program is built up from 
the ground locally. Further, the program is based on already established organizations, 
mainly primary care, specialist in geriatric and the elderly organization within the 
municipality which is standard all around Sweden. Moreover the program works within 
the general laws and recommendations from the authorities in Sweden. In this respect 
the tradition of local government within the Nordic countries [133] might be of help to 
new programs.  
 
Another problematic limitation with this study is that local traditions and regulations 
regarding the support of the demented patients provided by the municipalities changed 
during the study, and could affect the results? Further, if new regulation and laws were 
implemented during the investigation period further focusing on the care of the 
demented? In order to address this question we analyzed locally significant 
confounders such as changes of organization, new standards etc. that might interfere 
during the period from 2000 to 2005. However, no such major local confounders were 
identified. 
 
6.3.3 Establishing of the diagnose 
 
We found 153 cases per year during the observation period, which was almost the 
number expected [4]. This concordance might, however, be a coincidence. We did not 
account for potentially missed diagnosis by the GP. Additionally, diagnoses may 
simply be inaccurate. There was no “gold standard.” Also, some cases may have come 
to be diagnosed later, and effectivly missed in incidence figures for a given year. 
However, the rather high (within the mild dementia range) MMSE scores support the 
hypothesis that mostly new cases are diagnosed. Fourth, at the beginning of the 
program, prevalence estimates indicated that approximately 400 cases were not yet 
identified prior to introduction of the program. During the study period 755 new 
patients were diagnosed. Thus, the doubling of known cases from 1997 (31%) to 2005 
(63%) suggests diagnostic improvement. The pertinent question could be raised why 
not 100% of all patients are identified? Hypothetical some milder cases has not yet 
been identified. Further with multiple diseases with cognitive problem where the other 
diseases is more in focus. Furthermore patients who not want to know whit caregivers 
still supporting the needs. Finally, we have used the same geographical area as its own 
comparison. A control area could be an option, but such an approach is also 
problematic. However as the program continues all patients will soon or later be 
incorporated in the program. 
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The patients in our sample were a little older than in samples from some earlier 
publications [175, 176]. It might be argued that the patients were somewhat older than 
those newly diagnosed dementia patients generally presented in studies performed at 
specialist clinics. On the other hand that the average age is only three years older in the 
primary care population than that found in this area in a previous study [168]. We 
believe that the reason for the younger population at specialist clinics is due to 
preselection, where there is a tendency of seeing more patients who are still working 
age since such would be the case with patients having early onset of AD [175]. The 
patients diagnosed with dementia (positive cases) do not necessarily represent the “true 
cases”. The diagnosis is a result of a diagnostic process performed by the clinician after 
an individual evaluation. Furthermore, it is not possible to say that an investigation on 
the primary care level is “better” or “more cost effective” than on a specialist level. In 
order to analyze the cost effectiveness of a dementia diagnostic process, another study 
design is needed. Another problem is that ideally, the diagnostic investigation should be 
initiated early in new cases (incident cases) but is often delayed due to the complex and 
vague early symptoms.  
 
6.3.4 Drugs utilization in elderly 
 
A pertinent question is whether the dementia program had an influence on perscription 
practices, and if so, in what way? Clearly, one part of the program focuses on 
optimizing pharmacological treatment, even if this is not the main goal in the dementia 
investigation and the diagnose process. In addition we have seen interest among general 
practitioners for understanding the aging brain and its vulnerability for drugs. Thus, it is 
reasonable to assume that this may have had a positive influence on the drug use in the 
elderly in Kalmar. However, to our knowledge, up until now there are no dementia ore 
elderly management programs in the literature that also suggest changes in prescribing 
for long term [71].  
 
As a result of the dementia program (2000-2005) 1294 cognitively-impaired patients 
were identified in primary care [75] (corresponding to over 10% of 65 year and near 
15% of 75 year olds in the municipality). All of these patients were evaluated regarding 
their drug use. The demographic characteristics of the elderly population in the Kalmar 
municipality are comparable to that of Sweden. Thus, suggest generalizability of the 
finding in this thesis to the rest of the country. 
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6.3.5 Economical issues and resource 
utilization 
 
This thesis was not designed to analyze cost-effectiveness, since no comparison group 
was included from the beginning. Thus no statement of cost-effectiveness can be made. 
From a pragmatic cost-consequence viewpoint, there are indications that the program 
improves the quality of dementia diagnoses (the outcome) without increasing the costs. 
 
6.3.5.1 Primary care  
 
There are some drawbacks with this study that should be further investigated. Since this 
project partly focuses on the diagnostic procedure, the proportion of patients 
undergoing an investigation in primary care is probably higher in Kalmar than in other 
parts of Sweden. It is therefore difficult to apply the cost to the rest of Sweden, as 
dementia programs are not yet implemented in many areas. The unit costs may also 
vary in different parts of Sweden depending upon available resources (specialists, 
neuropsychologists etc). The sample in Study 2 was rather small, which makes it 
difficult to draw general conclusions. We have identified differences in costs between 
primary and specialist care with a specific distribution of costs in each group. It would 
therefore, however, be interesting to expand the project to other areas for a greater 
sample size. There are some limitations in this study regarding generalization of the 
cost for dementia investigation in Kalmar compared to the rest of Sweden. Recently 
presentation shows a higher cost for dementia investigating in a specialist setting from 
the SveDem database [177]. Most driven by investigations at the specialist level such a 
neuropsychological tests, lumbar puncture and brain images. From an international 
perspective, and to the best of our knowledge, there are no earlier publications that 
describe the cost of a dementia investigation. There is, however, a presentation of 
calculated international costs of diagnostic procedures [132]. This analysis shows a 
high variability of procedures used, and thus different costs, in the dementia diagnostic 
process between countries. No increase of budget was allocated for introducing the 
dementia disease management program in Kalmar, and no extra cost can be identified 
retrospectively. Thus the implementation was done within already existing resources. 
We could not argue that this was the optimal use of allocated resources. On the other 
hand we know that patients with dementia in early stages used primary care resources 
to a higher extent [136, 144] Further we did not identify an increase use of the 
resources in the primary care in our studies in this thesis. Thus the economical part is 
included not as an incentive, but as suggesting to be better resource utilization. 
 
6.3.5.2 Municipality 
 
The municipal costs were studied in a “bottom up” model (the real cost for dementia in 
the municipality). The comparison to the rest of Sweden is therefore somewhat 
problematic as these costs were not analyzed in a similar way. In spite of this it is 
positive to see that the cost appear similar. This suggests that a careful comparison is 
possible and therefore supports the idea that the cost for dementia in Kalmar with the 
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DMP is not higher than the cost in the rest of Sweden. If a difference may seen is it a 
lower cost in Kalmar than rest of the country, suggesting better resource utilization.  
Finally it is uncertain if all patients with dementia using municipal resources are 
identified in this “bottom up” model, as compared to the estimated cost for the whole of 
Sweden. For Kalmar there are probably patients missing due to the long period that the 
running of the dementia program. In addition, if there are missing patients they are 
using resources probably due to other reasons than dementia. Otherwise, dementia 
would be a main problem they would probably be included in the dementia program. 
Further studies should have a more prospective approach when including a control area 
even though this also will create problems due to difficulties of identification and 
diagnose which may contaminate the control area. The conclusion is that even with its 
limitations we find that the implementation of the dementia program are suggesting a 
lower cost for dementia in the municipality. The decreasing of the costs for the 
municipality will spill over with a higher cost in the primary care system may be a 
crucial risk. However, the dementia program was implemented within an unchanged 
budget via reallocation of the recourses.  
 
6.3.6  Generalizability overall 
 
In summary we find it possible to generalize the effects of the dementia management 
program of dementia in Kalmar to at least to the rest of Sweden. Moreover, suggesting 
the results in this thesis a carefully generalizability of the findings in this thesis to the 
Nordic countries [133] in general with local adaptation due to regional differences and 
traditions. 
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7 CONCLUSIONS AND FURTHER PERSPECTIVES  
 
7.1 CONCLUSIONS 
 
All suggested hypotheses in this project were confirmed or pending to be confirmed: 
 
 The dementia management program is reliable to defined most of the new 
patients per year. (Paper I) 
o Confirmed 
 What is the (mean) cost of a complete assessment for dementia at the level of 
(specialist or PCU), and how does this compare with the total cost of dementia 
assessment, treatment, and care during the full course of disease? (Paper II) 
o Confirmed 
 The dementia management program has additional influence on prescription 
patterns in the elderly population, to a more proper use of psychotropic, 
including sedatives, dementia drugs and drugs with anticholinergic properties. 
(Paper III) 
o Confirmed 
 Implementation of dementia management programs does not increase cost 
burden of managing dementia for the municipality. (Paper IV) 
o Confirmed 
 The dementia management program is at least cost neutral when applied in 
both county council and municipality. (Paper I, III and IV) 
o Pending to be confirmed 
 
7.2 FUTURE PERSPECTIVES 
 
To confirm the results from this thesis a setting with controlled data and analyses of the 
cost and the consequences should a controlled setting be appropriate to use. After the 
presentation of the new Swedish dementia guidelines in 2010 [32] would this be 
complicated to perform in Sweden.  
 
In this study we excluded QOL both from a patient and a caregiver perspective. In a 
broader perspective, analyzing a dementia program could utilize QOL data. Further to 
investigate is, if and how the QOL for the patients and the caregivers is changing 
during the years as long as the disease progress.  
 
Moreover the quality of the diagnose in a primary care setting and specialist is of 
interest to analyze. In respect to has it is performed in a dementia program such as this. 
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Cognitive deficits are an important area for further evaluation by a range of healthcare 
providers, such as in the emergency department, medicine, as well as care provided by 
surgical, orthopaedic, and psychiatric units. 
 
The economical aspect of dementia is of further interest for in view of the anticipated 
increase in the incidence in coming years. Thus if we aim to maintain a high quality 
level, or improve the dementia care in the future we have to have better knowledge of 
the economical perspective in dementia. The different economical steering instruments 
are of interest to investigate in order to fulfill the intentions of dementia care. The 
program in Kalmar started without economical steering. But if similar program follows 
the intentions of the new Swedish guidelines shall be implemented in general, the 
effects of economical steering instrument is of interests to investigate. Instruments such 
as knowledge, economical and process steering, together with a similar program. 
Further, if or what type steering activity will have the most preferable influence. 
Example of this can be changing the economical input to the GP to be a “Gate Opener” 
rather than a “Gate Keeper” when a patient with early cognitive problems is presented.  
 
Regulations, laws and governmental steering are ongoing processes. The tradition in 
the Nordic countries is a decentralized process. The regional differences in treatment of 
AD can be associated to that patients with cognitive problems have difficulties to be 
visualized. Thus, when patients and caregivers’ voice is not enough there is a risk that 
those persons are marginalized within the system while all the resources are used 
elsewhere. Perhaps a more centralized process is to be advocated in order to protect the 
equity geographically, social and economical, between genders and between diagnostic 
groups. How to address this in the best way has to be further analyzed. 
 
Finally, with visualization, identification, diagnosing and targeted treatment in a 
structural dementia management program, we suggest a better care of patient with 
dementia in an early phase and as the disease progress. All this is taking place together 
and suggests more optimal resource utilization for the benefit of the patients and their 
caregivers. With future treatment may offer possibilities to modify disease and new 
techniques and innovations will rephrase the questions that shall be offered this, what 
parameter shall be prioritized to this treatment and who shall diagnose and initiate this 
treatment. Thus have we already today start to prepare for these issues. 
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8 EPILOGUE  
 
During the work with this thesis about the Kalmar dementia program, the question of 
visibility of the dementia disease has often been discussed. The question of what will 
happen with this project is also being asked. Will it survive in the new era of the right 
to chose the provider “vårdvalet” (addressing the cognitive problem for the patients to 
chose the best for them self), new organization, new treatments, new regulations and 
when devoted people how will leave the “ship”. Certainly economical steering [174] 
can have an effect to the future. If we introduce a system supporting the process in a 
disease instead of rather than just a simple cost model like to be “paid per 
appointment”.  
 
Operations Management in charge of the implementation of the new guidelines could 
be a framework to solve resistance to implementation and stimulates horizontal and 
more functional driven activities. Moreover the lane-production organization is a 
method considers helping improve the process that focus on patients and caregivers 
(costumers). Its attributes could be a solution who is coping with the need of patients 
with chronic disease and who are particularly vulnerable due to cognitive impairment.  
 
Regarding the Nordic and Swedish tradition of local governance it can be argued that if 
this would not be the case none of this would have happened. Further in the future with 
new possibility’s to treat dementia and Alzheimer’s disease in particular, the need for a 
functional organization targeting the diagnose process will be of most interest for the 
patients and the society as a whole, all in a frame of reasonable and justified costs.  
 
*** 
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